Pharmacogenomics — MCQs

Q: Testing of HLA-B' 5701 is recommended prior to initiation of which antiretroviral agent?

Abacavir. The correct answer is **Abacavir (Option D)**. **1. Why Abacavir is Correct:** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) associated with a severe, potentially life-threatening **Hypersensitivity Reaction (HSR)** [1]. This reaction is strongly linked to the presence of the **HLA-B*57:01** allele. In individuals carrying this allele, abacavir binds to the HLA-B*57:01 protein, altering the shape of the antigen-binding cleft [1]. This causes the immune system to recognize self-peptides as foreign, triggering a massive T-cell response. Screening for this allele is now a standard of care; if a patient tests positive, abacavir is strictly contraindicated [1]. **2. Why Other Options are Incorrect:** * **Atazanavir (A):** A Protease Inhibitor (PI) known for causing unconjugated hyperbilirubinemia (jaundice) by inhibiting the UGT1A1 enzyme, but it is not linked to HLA-B*57:01 [1]. * **Nelfinavir (B):** An older PI primarily associated with gastrointestinal side effects (diarrhea). No specific HLA screening is required. * **Raltegravir (C):** An Integrase Strand Transfer Inhibitor (INSTI). While it can rarely cause Stevens-Johnson Syndrome (SJS), there is no routine pharmacogenetic screening recommended prior to its use. **3. High-Yield Clinical Pearls for NEET-PG:** * **Abacavir HSR Symptoms:** Fever, rash, GI distress, and respiratory symptoms. **Re-challenge** after a suspected reaction is **fatal**. * **Other High-Yield HLA Associations:** * **HLA-B*15:02:** Carbamazepine-induced SJS/TEN (specifically in Asian populations). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR). * **Mnemonic:** "A-B-C" — **A**bacavir **B**inds **C**left of HLA-B*57:01.

Q: Which HLA gene is associated with abacavir hypersensitivity?

B57. **Explanation:** **Correct Option: D (HLA-B*57:01)** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in HIV treatment. Approximately 5–8% of patients develop a potentially fatal **Abacavir Hypersensitivity Syndrome (AHS)**, characterized by fever, rash, and gastrointestinal symptoms. This reaction is strongly associated with the **HLA-B*57:01** allele. The drug binds to the antigen-binding cleft of this specific HLA molecule, altering the repertoire of self-peptides presented to T-cells, which triggers an autoimmune-like systemic inflammatory response. Screening for this allele is mandatory before initiating abacavir to prevent AHS. **Incorrect Options:** * **A (B5):** This is a broad serotype that includes B51 and B52 but is not specifically linked to abacavir. * **B (B51):** This allele is the classic genetic marker associated with **Behçet’s Disease** (characterized by oral/genital ulcers and uveitis). * **C (DQ2):** This is an HLA Class II allele strongly associated with **Celiac Disease** (along with HLA-DQ8). **High-Yield Clinical Pearls for NEET-PG:** 1. **Mandatory Screening:** If a patient tests positive for HLA-B*57:01, Abacavir is strictly **contraindicated** and should be listed as an allergy in their records. 2. **Re-challenge Warning:** Never re-challenge a patient with abacavir if AHS is suspected; it can lead to rapid, fatal hypotension and multi-organ failure. 3. **Other HLA-Drug Associations:** * **HLA-B*15:02:** Carbamazepine-induced Stevens-Johnson Syndrome (SJS) (especially in Asians). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR).

Q: All of the following drugs cause hemolysis in G-6PD deficiency except?

Erythromycin. ### Explanation **Concept Overview:** Glucose-6-Phosphate Dehydrogenase (G6PD) is a critical enzyme in the pentose phosphate pathway that maintains the supply of **reduced glutathione**. This molecule protects red blood cells (RBCs) from oxidative stress. In G6PD deficiency, exposure to oxidizing agents leads to the denaturation of hemoglobin (forming **Heinz bodies**) and subsequent hemolysis. **Why Erythromycin is the Correct Answer:** **Erythromycin** is a macrolide antibiotic that does not possess significant oxidizing properties. It is considered safe to use in patients with G6PD deficiency. It does not interfere with the redox state of the erythrocyte or trigger the destruction of RBCs. **Analysis of Incorrect Options:** * **Primaquine:** This is the classic "textbook" trigger. It is an antimalarial that generates reactive oxygen species (ROS), causing severe hemolysis in G6PD-deficient individuals. * **Nitrofurantoin:** A urinary antiseptic known to cause oxidative stress. It is strictly contraindicated in G6PD-deficient patients due to the high risk of hemolytic anemia. * **Sulfonamides (e.g., Sulfamethoxazole):** These drugs act as oxidizing agents. They are well-documented triggers for hemolytic crises in affected patients. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** G6PD deficiency is an **X-linked recessive** disorder (more common in males). * **Peripheral Smear Findings:** Look for **Heinz bodies** (denatured hemoglobin) and **Bite cells** (degmacytes) formed by splenic macrophages removing these bodies. * **Other Common Triggers:** Dapsone, Rasburicase, Methylene blue, and **Fava beans** (Favism). * **Safe Alternatives:** Penicillins, Cephalosporins, and Macrolides (like Erythromycin) are generally safe. * **Key Contraindication:** Never give **Primaquine** without first screening the patient for G6PD levels.

Q: Therapeutic drug monitoring is used in which of the following medications?

Digoxin. **Explanation:** **Therapeutic Drug Monitoring (TDM)** is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **therapeutic window**. It is primarily indicated for drugs with a **narrow therapeutic index**, where the difference between the effective dose and the toxic dose is minimal. **Why Digoxin is the Correct Answer:** Digoxin has a very narrow therapeutic index (typically **0.5–2.0 ng/mL**). Small fluctuations in serum levels can lead to life-threatening toxicity (arrhythmias, xanthopsia, or gastrointestinal distress). Factors like renal impairment, hypokalemia, and drug interactions (e.g., with Amiodarone or Verapamil) significantly alter its pharmacokinetics, making TDM essential for safety and efficacy. **Why Other Options are Incorrect:** * **A. Diuretics:** Their effect is easily monitored clinically by measuring urine output, body weight, blood pressure, and serum electrolytes. * **B. Metformin:** Its efficacy is monitored by measuring clinical markers like blood glucose levels and HbA1c, rather than plasma drug concentrations. * **C. Levodopa:** The clinical response (improvement in Parkinsonian symptoms) and the appearance of side effects (dyskinesia) are used to titrate the dose. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Remember the mnemonic **"THEAL"** – **T**ricyclic antidepressants, **H**eart meds (Digoxin, Quinidine), **E**pilepsy meds (Phenytoin, Carbamazepine), **A**minoglycosides (Gentamicin), and **L**ithium. * **Sampling Time:** For Digoxin, TDM should be performed at least **6–8 hours after the last dose** (post-distribution phase) to ensure accurate results. * **Exceptions:** TDM is **not** useful for drugs with "hit and run" pharmacokinetics (e.g., Omeprazole) or those with easily measurable physiological endpoints (e.g., Warfarin via PT/INR).

Q: Which of the following is an ionotropic receptor?

Nicotinic cholinergic receptor. **Explanation:** Receptors are classified into four major types based on their structure and signaling mechanism. **Ionotropic receptors** (Ligand-gated ion channels) are transmembrane proteins that open or close in response to the binding of a chemical messenger, allowing the rapid flow of ions across the cell membrane. **Why Option B is Correct:** The **Nicotinic Cholinergic Receptor (nAChR)** is a classic example of an ionotropic receptor. It is a pentameric structure that, upon binding with Acetylcholine, undergoes a conformational change to open a central pore. This allows the influx of **Sodium (Na+)** and efflux of **Potassium (K+)**, leading to rapid depolarization. These are found at the neuromuscular junction (NMJ) and autonomic ganglia. **Why Other Options are Incorrect:** * **A. Muscarinic Cholinergic Receptor:** These are **G-Protein Coupled Receptors (GPCRs)** or metabotropic receptors. They act via second messengers (like IP3/DAG or cAMP) and are slower than ionotropic receptors. * **C. Glucocorticoid Receptor:** These are **Intracellular/Nuclear receptors**. They act as ligand-activated transcription factors that regulate gene expression in the nucleus. * **D. Insulin Receptor:** This is an **Enzyme-linked receptor** (specifically, a Receptor Tyrosine Kinase). Binding of insulin leads to autophosphorylation of tyrosine residues. **High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (milliseconds) > GPCRs (seconds) > Enzyme-linked (minutes/hours) > Nuclear receptors (hours/days). * **Other Ionotropic Examples:** GABA-A (Chloride channel), Glycine, 5-HT3 (the only ionotropic Serotonin receptor), and NMDA/AMPA receptors. * **Pharmacogenomics Link:** Mutations in the subunits of the nicotinic receptor can lead to conditions like Congenital Myasthenic Syndromes.

Q: HLA* 1502 is a genetic marker associated with which of the following conditions?

Stevens-Johnson Syndrome. ### Explanation **Correct Answer: C. Stevens-Johnson Syndrome** The **HLA-B*1502** allele is a critical pharmacogenetic marker strongly associated with an increased risk of **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)** in patients treated with **Carbamazepine**. This association is particularly prevalent in populations of **East Asian and Southeast Asian** descent (e.g., Han Chinese, Thai, Indians). The mechanism involves a T-cell mediated hypersensitivity reaction where the drug (Carbamazepine) binds to the HLA-B*1502 molecule, triggering an immune response against keratinocytes. Due to this high correlation, the FDA recommends screening for this allele in high-risk populations before initiating Carbamazepine therapy. **Analysis of Incorrect Options:** * **A. Systemic Lupus Erythematosus (SLE):** Associated primarily with **HLA-DR2** and **HLA-DR3**. Drug-induced SLE is linked to "slow acetylators" (NAT2 deficiency) taking drugs like Procainamide or Hydralazine. * **B. Polyarteritis Nodosa:** Strongly associated with **Hepatitis B surface antigen (HBsAg)** positivity, not a specific HLA-B allele. * **D. Seronegative Spondyloarthritis:** This group of disorders (including Ankylosing Spondylitis) is classically associated with **HLA-B27**. **High-Yield Clinical Pearls for NEET-PG:** * **HLA-B*5701:** Associated with hypersensitivity to **Abacavir** (NRTI). * **HLA-B*5801:** Associated with SJS/TEN induced by **Allopurinol** (especially in Han Chinese). * **HLA-A*3101:** Another marker for Carbamazepine-induced skin reactions, more common in Europeans and Japanese. * **Drug of choice for SJS/TEN:** Supportive care and IV Immunoglobulins (IVIG). Cyclosporine is also used.

Q: Which of the following drugs is hydrolyzed by a plasma esterase that has abnormally low activity in about 1 in every 2500 humans?

Succinylcholine. **Explanation:** **1. Correct Option: Succinylcholine** Succinylcholine is a depolarizing neuromuscular blocker used for rapid sequence induction. Its action is normally terminated within 5–10 minutes because it is rapidly hydrolyzed by **Butyrylcholinesterase (BChE)**, also known as **Pseudocholinesterase** or **Plasma Cholinesterase**. About 1 in 2500 individuals (of European descent) carries an autosomal recessive trait for **atypical pseudocholinesterase**. In these patients, the enzyme has a low affinity for the drug, leading to a failure to hydrolyze succinylcholine. This results in prolonged neuromuscular blockade and life-threatening respiratory paralysis, a clinical condition known as **Succinylcholine Apnea**. **2. Incorrect Options:** * **Ethanol:** Primarily metabolized in the liver by Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH). While ALDH deficiency is common in Asian populations (causing "flushing"), it is not a plasma esterase. * **Rifampicin:** A potent inducer of Cytochrome P450 enzymes. It is metabolized via hepatic deacetylation, not plasma esterases. * **Cimetidine:** An H2 blocker and a well-known enzyme inhibitor. It is eliminated via a combination of hepatic metabolism and renal excretion. **3. High-Yield Clinical Pearls for NEET-PG:** * **Dibucaine Number:** This is the diagnostic test for atypical pseudocholinesterase. Dibucaine inhibits normal enzyme by 80%, but atypical enzyme by only 20%. A **low Dibucaine number** indicates a high risk for apnea. * **Management:** If apnea occurs, the patient must be maintained on **mechanical ventilation** until the drug wears off naturally. * **Mivacurium:** Another neuromuscular blocker also metabolized by pseudocholinesterase that can cause prolonged paralysis in these patients.

Pharmacogenomics Indian Medical PG Practice Questions and MCQs

Question 1: Testing of HLA-B' 5701 is recommended prior to initiation of which antiretroviral agent?

A. Atazanavir
B. Nelfinavir
C. Raltegravir
D. Abacavir (Correct Answer)

Explanation: The correct answer is **Abacavir (Option D)**. **1. Why Abacavir is Correct:** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) associated with a severe, potentially life-threatening **Hypersensitivity Reaction (HSR)** [1]. This reaction is strongly linked to the presence of the **HLA-B*57:01** allele. In individuals carrying this allele, abacavir binds to the HLA-B*57:01 protein, altering the shape of the antigen-binding cleft [1]. This causes the immune system to recognize self-peptides as foreign, triggering a massive T-cell response. Screening for this allele is now a standard of care; if a patient tests positive, abacavir is strictly contraindicated [1]. **2. Why Other Options are Incorrect:** * **Atazanavir (A):** A Protease Inhibitor (PI) known for causing unconjugated hyperbilirubinemia (jaundice) by inhibiting the UGT1A1 enzyme, but it is not linked to HLA-B*57:01 [1]. * **Nelfinavir (B):** An older PI primarily associated with gastrointestinal side effects (diarrhea). No specific HLA screening is required. * **Raltegravir (C):** An Integrase Strand Transfer Inhibitor (INSTI). While it can rarely cause Stevens-Johnson Syndrome (SJS), there is no routine pharmacogenetic screening recommended prior to its use. **3. High-Yield Clinical Pearls for NEET-PG:** * **Abacavir HSR Symptoms:** Fever, rash, GI distress, and respiratory symptoms. **Re-challenge** after a suspected reaction is **fatal**. * **Other High-Yield HLA Associations:** * **HLA-B*15:02:** Carbamazepine-induced SJS/TEN (specifically in Asian populations). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR). * **Mnemonic:** "A-B-C" — **A**bacavir **B**inds **C**left of HLA-B*57:01.

Question 2: Which HLA gene is associated with abacavir hypersensitivity?

A. B5
B. B51
C. DQ2
D. B57 (Correct Answer)

Explanation: **Explanation:** **Correct Option: D (HLA-B*57:01)** Abacavir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in HIV treatment. Approximately 5–8% of patients develop a potentially fatal **Abacavir Hypersensitivity Syndrome (AHS)**, characterized by fever, rash, and gastrointestinal symptoms. This reaction is strongly associated with the **HLA-B*57:01** allele. The drug binds to the antigen-binding cleft of this specific HLA molecule, altering the repertoire of self-peptides presented to T-cells, which triggers an autoimmune-like systemic inflammatory response. Screening for this allele is mandatory before initiating abacavir to prevent AHS. **Incorrect Options:** * **A (B5):** This is a broad serotype that includes B51 and B52 but is not specifically linked to abacavir. * **B (B51):** This allele is the classic genetic marker associated with **Behçet’s Disease** (characterized by oral/genital ulcers and uveitis). * **C (DQ2):** This is an HLA Class II allele strongly associated with **Celiac Disease** (along with HLA-DQ8). **High-Yield Clinical Pearls for NEET-PG:** 1. **Mandatory Screening:** If a patient tests positive for HLA-B*57:01, Abacavir is strictly **contraindicated** and should be listed as an allergy in their records. 2. **Re-challenge Warning:** Never re-challenge a patient with abacavir if AHS is suspected; it can lead to rapid, fatal hypotension and multi-organ failure. 3. **Other HLA-Drug Associations:** * **HLA-B*15:02:** Carbamazepine-induced Stevens-Johnson Syndrome (SJS) (especially in Asians). * **HLA-B*58:01:** Allopurinol-induced severe cutaneous adverse reactions (SCAR).

Question 3: All of the following drugs cause hemolysis in G-6PD deficiency except?

A. Primaquine
B. Nitrofurantoin
C. Sulfonamides
D. Erythromycin (Correct Answer)

Explanation: ### Explanation **Concept Overview:** Glucose-6-Phosphate Dehydrogenase (G6PD) is a critical enzyme in the pentose phosphate pathway that maintains the supply of **reduced glutathione**. This molecule protects red blood cells (RBCs) from oxidative stress. In G6PD deficiency, exposure to oxidizing agents leads to the denaturation of hemoglobin (forming **Heinz bodies**) and subsequent hemolysis. **Why Erythromycin is the Correct Answer:** **Erythromycin** is a macrolide antibiotic that does not possess significant oxidizing properties. It is considered safe to use in patients with G6PD deficiency. It does not interfere with the redox state of the erythrocyte or trigger the destruction of RBCs. **Analysis of Incorrect Options:** * **Primaquine:** This is the classic "textbook" trigger. It is an antimalarial that generates reactive oxygen species (ROS), causing severe hemolysis in G6PD-deficient individuals. * **Nitrofurantoin:** A urinary antiseptic known to cause oxidative stress. It is strictly contraindicated in G6PD-deficient patients due to the high risk of hemolytic anemia. * **Sulfonamides (e.g., Sulfamethoxazole):** These drugs act as oxidizing agents. They are well-documented triggers for hemolytic crises in affected patients. **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** G6PD deficiency is an **X-linked recessive** disorder (more common in males). * **Peripheral Smear Findings:** Look for **Heinz bodies** (denatured hemoglobin) and **Bite cells** (degmacytes) formed by splenic macrophages removing these bodies. * **Other Common Triggers:** Dapsone, Rasburicase, Methylene blue, and **Fava beans** (Favism). * **Safe Alternatives:** Penicillins, Cephalosporins, and Macrolides (like Erythromycin) are generally safe. * **Key Contraindication:** Never give **Primaquine** without first screening the patient for G6PD levels.

Question 4: Therapeutic drug monitoring is used in which of the following medications?

A. Diuretic
B. Metformin
C. Levodopa
D. Digoxin (Correct Answer)

Explanation: **Explanation:** **Therapeutic Drug Monitoring (TDM)** is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **therapeutic window**. It is primarily indicated for drugs with a **narrow therapeutic index**, where the difference between the effective dose and the toxic dose is minimal. **Why Digoxin is the Correct Answer:** Digoxin has a very narrow therapeutic index (typically **0.5–2.0 ng/mL**). Small fluctuations in serum levels can lead to life-threatening toxicity (arrhythmias, xanthopsia, or gastrointestinal distress). Factors like renal impairment, hypokalemia, and drug interactions (e.g., with Amiodarone or Verapamil) significantly alter its pharmacokinetics, making TDM essential for safety and efficacy. **Why Other Options are Incorrect:** * **A. Diuretics:** Their effect is easily monitored clinically by measuring urine output, body weight, blood pressure, and serum electrolytes. * **B. Metformin:** Its efficacy is monitored by measuring clinical markers like blood glucose levels and HbA1c, rather than plasma drug concentrations. * **C. Levodopa:** The clinical response (improvement in Parkinsonian symptoms) and the appearance of side effects (dyskinesia) are used to titrate the dose. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Remember the mnemonic **"THEAL"** – **T**ricyclic antidepressants, **H**eart meds (Digoxin, Quinidine), **E**pilepsy meds (Phenytoin, Carbamazepine), **A**minoglycosides (Gentamicin), and **L**ithium. * **Sampling Time:** For Digoxin, TDM should be performed at least **6–8 hours after the last dose** (post-distribution phase) to ensure accurate results. * **Exceptions:** TDM is **not** useful for drugs with "hit and run" pharmacokinetics (e.g., Omeprazole) or those with easily measurable physiological endpoints (e.g., Warfarin via PT/INR).

Question 5: Which of the following is an ionotropic receptor?

A. Muscarinic cholinergic receptor
B. Nicotinic cholinergic receptor (Correct Answer)
C. Glucocorticoid receptor
D. Insulin receptor

Explanation: **Explanation:** Receptors are classified into four major types based on their structure and signaling mechanism. **Ionotropic receptors** (Ligand-gated ion channels) are transmembrane proteins that open or close in response to the binding of a chemical messenger, allowing the rapid flow of ions across the cell membrane. **Why Option B is Correct:** The **Nicotinic Cholinergic Receptor (nAChR)** is a classic example of an ionotropic receptor. It is a pentameric structure that, upon binding with Acetylcholine, undergoes a conformational change to open a central pore. This allows the influx of **Sodium (Na+)** and efflux of **Potassium (K+)**, leading to rapid depolarization. These are found at the neuromuscular junction (NMJ) and autonomic ganglia. **Why Other Options are Incorrect:** * **A. Muscarinic Cholinergic Receptor:** These are **G-Protein Coupled Receptors (GPCRs)** or metabotropic receptors. They act via second messengers (like IP3/DAG or cAMP) and are slower than ionotropic receptors. * **C. Glucocorticoid Receptor:** These are **Intracellular/Nuclear receptors**. They act as ligand-activated transcription factors that regulate gene expression in the nucleus. * **D. Insulin Receptor:** This is an **Enzyme-linked receptor** (specifically, a Receptor Tyrosine Kinase). Binding of insulin leads to autophosphorylation of tyrosine residues. **High-Yield Clinical Pearls for NEET-PG:** * **Fastest Receptors:** Ionotropic receptors (milliseconds) > GPCRs (seconds) > Enzyme-linked (minutes/hours) > Nuclear receptors (hours/days). * **Other Ionotropic Examples:** GABA-A (Chloride channel), Glycine, 5-HT3 (the only ionotropic Serotonin receptor), and NMDA/AMPA receptors. * **Pharmacogenomics Link:** Mutations in the subunits of the nicotinic receptor can lead to conditions like Congenital Myasthenic Syndromes.

Question 6: Which of the following drugs does not act on cytoplasmic receptors?

A. Corticosteroids
B. Vitamin D
C. Aldosterone
D. Thyroxine (Correct Answer)

Explanation: **Explanation:** The mechanism of action of hormones depends on their lipid solubility and the location of their specific receptors. Receptors for lipid-soluble ligands are classified as **Intracellular Receptors**, which are further divided into **Cytoplasmic** and **Nuclear** types. **Why Thyroxine is the correct answer:** Thyroxine (T3/T4) is unique because, although it is lipid-soluble, its receptors are located **constitutively inside the nucleus** (bound to DNA). Unlike steroid hormones that must translocate from the cytoplasm to the nucleus, thyroid hormone receptors are already present on the thyroid hormone response elements (TRE) of the target genes. Therefore, Thyroxine does **not** act on cytoplasmic receptors. **Analysis of Incorrect Options:** * **Corticosteroids (Glucocorticoids):** These act on **Type 1 Cytoplasmic receptors**. Upon binding, the receptor-ligand complex dissociates from heat shock proteins (hsp90) and translocates into the nucleus. * **Aldosterone (Mineralocorticoids):** Similar to glucocorticoids, aldosterone binds to mineralocorticoid receptors located primarily in the **cytoplasm** of the renal collecting duct cells. * **Vitamin D:** While often grouped with nuclear receptors, the Vitamin D receptor (VDR) is primarily localized in the **cytoplasm** and moves to the nucleus upon activation (though some literature suggests a dual distribution, for NEET-PG purposes, it is categorized with steroids). **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Cytoplasmic Receptors:** "**C**an **A**ll **V**itamins **G**o?" (**C**orticosteroids, **A**ldosterone, **V**itamin D, **G**uanylyl cyclase - though the latter is an enzyme). * **Mnemonic for Nuclear Receptors:** "**R**etinoic acid **A**nd **T**hyroid" (**R**etinoic acid, **A**ndrogens/Estrogen/Progesterone*, **T**hyroid). * *Note:* Estrogen and Progesterone receptors are predominantly nuclear, similar to Thyroid hormone. * All intracellular receptors act as **ligand-activated transcription factors**, leading to altered mRNA synthesis and protein expression. This explains their **slow onset of action** (lag period).

Question 7: What is true about tachyphylaxis?

A. Direct sympathomimetic involved
B. Mechanism clearly understood
C. Ephedrine tachyphylaxis reversed with noradrenaline
D. Indirect sympathomimetics involved (Correct Answer)

Explanation: ### Explanation **Tachyphylaxis** is a pharmacological phenomenon characterized by a rapid decrease in response to a drug after repeated administration over a short period. It is a form of "acute tolerance" that cannot be overcome by increasing the dose. **Why Option D is Correct:** Tachyphylaxis is most classically associated with **indirect-acting sympathomimetics** (e.g., **Ephedrine, Tyramine, Amphetamine**). These drugs work by displacing stored norepinephrine (NE) from the presynaptic nerve terminals into the synaptic cleft. With repeated, frequent dosing, the available neuronal stores of NE become depleted faster than they can be replenished. Once the stores are exhausted, the drug loses its efficacy, leading to tachyphylaxis. **Analysis of Incorrect Options:** * **Option A:** Direct sympathomimetics (e.g., Adrenaline, Phenylephrine) act directly on receptors. While they can undergo receptor desensitization (downregulation) over a long period, they do not typically cause the rapid, store-depletion-driven tachyphylaxis seen with indirect agents. * **Option B:** The mechanism is not always "clearly understood" for every drug. While NE depletion explains ephedrine, other drugs (like Nitroglycerin) involve complex oxidative stress or enzyme inactivation mechanisms that are still being researched. * **Option C:** Ephedrine tachyphylaxis is **not** reversed by noradrenaline; rather, the *response* to ephedrine is lost because NE is gone. Administering exogenous NE would restore the physiological effect (vasoconstriction), but it does not "reverse" the exhaustion of the internal stores required for ephedrine to function. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Examples:** Ephedrine (nasal decongestants), Tyramine, Amphetamine, Nicotine, and Nitroglycerin (requires a "drug-free interval" to prevent tolerance). * **Key Distinction:** Unlike **Tolerance** (which develops slowly over weeks), **Tachyphylaxis** develops rapidly (minutes to hours). * **Mechanism:** Most commonly due to **depletion of endogenous mediators** or rapid receptor phosphorylation/internalization.

Question 8: HLA* 1502 is a genetic marker associated with which of the following conditions?

A. Systemic Lupus Erythematosus (SLE)
B. Polyarteritis Nodosa
C. Stevens-Johnson Syndrome (Correct Answer)
D. Seronegative Spondyloarthritis Syndrome

Explanation: ### Explanation **Correct Answer: C. Stevens-Johnson Syndrome** The **HLA-B*1502** allele is a critical pharmacogenetic marker strongly associated with an increased risk of **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)** in patients treated with **Carbamazepine**. This association is particularly prevalent in populations of **East Asian and Southeast Asian** descent (e.g., Han Chinese, Thai, Indians). The mechanism involves a T-cell mediated hypersensitivity reaction where the drug (Carbamazepine) binds to the HLA-B*1502 molecule, triggering an immune response against keratinocytes. Due to this high correlation, the FDA recommends screening for this allele in high-risk populations before initiating Carbamazepine therapy. **Analysis of Incorrect Options:** * **A. Systemic Lupus Erythematosus (SLE):** Associated primarily with **HLA-DR2** and **HLA-DR3**. Drug-induced SLE is linked to "slow acetylators" (NAT2 deficiency) taking drugs like Procainamide or Hydralazine. * **B. Polyarteritis Nodosa:** Strongly associated with **Hepatitis B surface antigen (HBsAg)** positivity, not a specific HLA-B allele. * **D. Seronegative Spondyloarthritis:** This group of disorders (including Ankylosing Spondylitis) is classically associated with **HLA-B27**. **High-Yield Clinical Pearls for NEET-PG:** * **HLA-B*5701:** Associated with hypersensitivity to **Abacavir** (NRTI). * **HLA-B*5801:** Associated with SJS/TEN induced by **Allopurinol** (especially in Han Chinese). * **HLA-A*3101:** Another marker for Carbamazepine-induced skin reactions, more common in Europeans and Japanese. * **Drug of choice for SJS/TEN:** Supportive care and IV Immunoglobulins (IVIG). Cyclosporine is also used.

Question 9: Which of the following drugs is hydrolyzed by a plasma esterase that has abnormally low activity in about 1 in every 2500 humans?

A. Ethanol
B. Rifampicin
C. Cimetidine
D. Succinylcholine (Correct Answer)

Explanation: **Explanation:** **1. Correct Option: Succinylcholine** Succinylcholine is a depolarizing neuromuscular blocker used for rapid sequence induction. Its action is normally terminated within 5–10 minutes because it is rapidly hydrolyzed by **Butyrylcholinesterase (BChE)**, also known as **Pseudocholinesterase** or **Plasma Cholinesterase**. About 1 in 2500 individuals (of European descent) carries an autosomal recessive trait for **atypical pseudocholinesterase**. In these patients, the enzyme has a low affinity for the drug, leading to a failure to hydrolyze succinylcholine. This results in prolonged neuromuscular blockade and life-threatening respiratory paralysis, a clinical condition known as **Succinylcholine Apnea**. **2. Incorrect Options:** * **Ethanol:** Primarily metabolized in the liver by Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH). While ALDH deficiency is common in Asian populations (causing "flushing"), it is not a plasma esterase. * **Rifampicin:** A potent inducer of Cytochrome P450 enzymes. It is metabolized via hepatic deacetylation, not plasma esterases. * **Cimetidine:** An H2 blocker and a well-known enzyme inhibitor. It is eliminated via a combination of hepatic metabolism and renal excretion. **3. High-Yield Clinical Pearls for NEET-PG:** * **Dibucaine Number:** This is the diagnostic test for atypical pseudocholinesterase. Dibucaine inhibits normal enzyme by 80%, but atypical enzyme by only 20%. A **low Dibucaine number** indicates a high risk for apnea. * **Management:** If apnea occurs, the patient must be maintained on **mechanical ventilation** until the drug wears off naturally. * **Mivacurium:** Another neuromuscular blocker also metabolized by pseudocholinesterase that can cause prolonged paralysis in these patients.

Question 10: Which statement related to the expiry date of a drug is true?

A. It is the date up to which the drug is likely to be fully potent and safe to take based on scientifically-sound product testing, if stored properly. (Correct Answer)
B. The maximum period of expiry is 3 years from the date of manufacture.
C. After the expiry period, there is a fall in the efficacy of the drug.
D. After the expiry period, the drug changes to more toxic compounds.

Explanation: **Explanation** The expiry date of a drug is a strictly regulated parameter determined by stability testing. **1. Why Option A is correct:** The expiry date represents the final day that the manufacturer guarantees the **full potency and safety** of a drug. This is based on real-time and accelerated stability studies. For a drug to be considered "within expiry," it must typically retain at least **90% of its labeled potency** and remain free from significant toxic degradation, provided it has been stored under the specific conditions (temperature, light, humidity) mentioned on the label. **2. Why the other options are incorrect:** * **Option B:** There is no universal "3-year" rule. The shelf life varies significantly depending on the chemical stability of the active pharmaceutical ingredient (API). Some drugs expire in 6 months, while others are stable for 5 years. * **Option C:** While efficacy *does* decrease over time, this is not the definition of the expiry date itself. Furthermore, many drugs remain 100% effective for a period after the date; the expiry is simply the legal limit of the manufacturer's guarantee. * **Option D:** While some drugs (like Tetracyclines) can degrade into toxic metabolites (e.g., causing Fanconi syndrome), this is the **exception, not the rule**. Most drugs simply lose potency rather than becoming acutely toxic. **High-Yield Clinical Pearls for NEET-PG:** * **The SLEP (Shelf Life Extension Program):** Studies by the FDA have shown many stockpiled drugs remain potent for years past their expiry, but for clinical practice, the labeled date is the legal standard. * **Tetracycline Warning:** Expired tetracycline is classically associated with **Fanconi Syndrome** (proximal renal tubular acidosis). * **Storage Matters:** Potency loss is accelerated by "vial-to-vial" variability and improper storage (e.g., leaving nitroglycerin in sunlight).

Question 11: A drug that binds to a receptor at a site distinct from the active site and alters the affinity of the receptor for the endogenous ligand is a:

A. Competitive antagonist
B. Inverse agonist
C. Partial agonist
D. Allosteric modulator (Correct Answer)

Explanation: ### Explanation **1. Why Allosteric Modulator is Correct:** The term **"allosteric"** (Greek: *allos* = other, *stereos* = space) refers to a binding site on a receptor that is topographically distinct from the orthosteric (active) site where the endogenous ligand binds [1]. * **Mechanism:** When an allosteric modulator binds, it induces a conformational change in the receptor [1]. This change can either increase (**Positive Allosteric Modulator/PAM**) or decrease (**Negative Allosteric Modulator/NAM**) the affinity or efficacy of the endogenous ligand for its active site [1]. Since the question specifies binding at a distinct site to alter affinity, it perfectly describes an allosteric modulator. **2. Why Other Options are Incorrect:** * **Competitive Antagonist:** These bind to the **same active site** as the endogenous ligand. They compete for the same "space," and their effect can be overcome by increasing the concentration of the agonist. * **Inverse Agonist:** These bind to the same receptor (often the active site) but produce an effect **opposite** to that of the agonist. They reduce the constitutive (basal) activity of the receptor. * **Partial Agonist:** These bind to the active site but produce only a sub-maximal response, even at 100% receptor occupancy [2]. They have an intrinsic activity between 0 and 1. **3. High-Yield Clinical Pearls for NEET-PG:** * **Classic Example:** **Benzodiazepines** are PAMs of the $GABA_A$ receptor. They do not open the channel themselves but increase the frequency of channel opening in the presence of GABA. * **Cinacalcet:** A PAM at the calcium-sensing receptor used in hyperparathyroidism. * **Maraviroc:** An allosteric antagonist (NAM) of the CCR5 receptor used in HIV treatment. * **Key Distinction:** Unlike competitive antagonists, allosteric modulators do not compete for the active site [1], meaning they can saturate their effect regardless of agonist concentration (ceiling effect), often making them safer in overdose.

Question 12: What is true about pKa?

A. The pH at which the ionized fraction of a drug equals its unionized fraction. (Correct Answer)
B. The pH at which the ionized fraction of a drug is greater than its unionized fraction.
C. The pH at which the ionized fraction of a drug is less than its unionized fraction.
D. The pH at which the ionized fraction of a drug is twice its unionized fraction.

Explanation: **Explanation:** The concept of **pKa** is fundamental to understanding drug absorption and distribution. [1] By definition, pKa is the negative logarithm of the acid dissociation constant ($K_a$). [1] It represents the specific **pH at which a drug exists in a state of equilibrium**, where exactly **50% of the drug is ionized (charged) and 50% is unionized (uncharged).** [1] This relationship is governed by the **Henderson-Hasselbalch equation**: [1] $pH = pKa + eg \log \frac{[Ionized]}{[Unionized]}$ (for acids) When $pH = pKa$, the log term becomes $\log(1)$, which is zero, confirming that the concentrations of ionized and unionized forms are equal. [1] **Analysis of Options:** * **Option A (Correct):** Accurately describes the equilibrium state where ionized fraction = unionized fraction. [1] * **Options B, C, and D:** These represent states where the pH has shifted away from the pKa. According to the principle, for a **weakly acidic drug**, if the pH is higher than the pKa, the ionized fraction increases. [1] For a **weakly basic drug**, if the pH is lower than the pKa, the ionized fraction increases. [2] **High-Yield Clinical Pearls for NEET-PG:** 1. **Lipid Solubility:** Only the **unionized** form of a drug is lipid-soluble and can cross biological membranes (cell membranes, blood-brain barrier). [1] 2. **Ion Trapping:** This principle is used in treating toxicity. To excrete a **weakly acidic drug** (like Aspirin), we **alkalinize the urine** (using Sodium Bicarbonate). [1] This increases the ionized fraction in the renal tubules, "trapping" the drug in the urine and preventing reabsorption. [1] 3. **Acidic Drugs:** Bind primarily to **Albumin**. 4. **Basic Drugs:** Bind primarily to **$\alpha_1$-acid glycoprotein**.

Question 13: Which drugs should be avoided in G6PD deficiency?

A. Dapsone (Correct Answer)
B. Metformin
C. Pregabalin
D. Rituximab

Explanation: **Explanation:** **1. Why Dapsone is the Correct Answer:** Glucose-6-Phosphate Dehydrogenase (G6PD) is a critical enzyme in the pentose phosphate pathway that maintains the pool of **reduced glutathione** in red blood cells (RBCs). Reduced glutathione acts as an antioxidant, neutralizing free radicals and reactive oxygen species (ROS). **Dapsone** is a potent oxidizing agent. In G6PD-deficient individuals, the RBCs cannot regenerate enough reduced glutathione to combat the oxidative stress caused by Dapsone. This leads to the oxidation of hemoglobin into **Heinz bodies**, resulting in membrane damage and **acute hemolytic anemia**. **2. Analysis of Incorrect Options:** * **Metformin (B):** A biguanide used in Type 2 Diabetes. Its primary side effect is lactic acidosis; it does not cause oxidative stress or hemolysis. * **Pregabalin (C):** A gabapentinoid used for neuropathic pain and seizures. It has no known interaction with the G6PD enzyme pathway. * **Rituximab (D):** A monoclonal antibody against CD20. While it can cause infusion reactions or cytopenias, it is not an oxidizing drug and is safe in G6PD deficiency. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "AAA" Rule:** Common triggers for G6PD hemolysis include **A**ntimalarials (Primaquine, Chloroquine), **A**ntibiotics (Sulfonamides, Dapsone, Nitrofurantoin), and **A**ntipyretics (high-dose Aspirin). * **Fava Beans:** Ingestion causes "Favism," a classic trigger for hemolysis in these patients. * **Peripheral Smear Findings:** Look for **Heinz Bodies** (denatured hemoglobin) and **Bite Cells** (degmacytes) formed when splenic macrophages pluck out these bodies. * **Inheritance:** It is an **X-linked recessive** disorder, making it more common in males.

Question 14: Loading dose depends on the following factors except:

A. Drug concentration to be achieved
B. Volume of distribution
C. Clearance of the drug (Correct Answer)
D. Bioavailability of drug

Explanation: The **Loading Dose (LD)** is a large initial dose given to achieve the therapeutic plasma concentration ($C_p$) as quickly as possible. It is primarily determined by the **volume of distribution ($V_d$)**, not by how fast the drug is removed from the body [1, 2]. **1. Why Clearance (C) is the correct answer:** Clearance refers to the rate at which the drug is removed from the plasma. It determines the **Maintenance Dose (MD)**, which is required to maintain a steady-state concentration [1]. Since the loading dose is designed to "fill the tank" (the volume of distribution) rather than replace ongoing losses, clearance does not influence its calculation. **2. Analysis of Incorrect Options:** * **Volume of Distribution ($V_d$):** This is the most critical factor. The formula for LD is: $LD = \frac{V_d \times Target C_p}{F}$. A drug with a high $V_d$ (sequestered in tissues) requires a higher loading dose to saturate those tissues and reach the target plasma level [1, 2]. * **Target Drug Concentration ($C_p$):** The desired therapeutic level directly dictates how much drug must be administered [1]. * **Bioavailability ($F$):** For non-intravenous routes, the fraction of the drug that reaches systemic circulation must be accounted for. If $F$ is low, the administered dose must be higher [1]. --- ### High-Yield Clinical Pearls for NEET-PG * **The Golden Rule:** Loading dose depends on **Volume of Distribution ($V_d$)**; Maintenance dose depends on **Clearance ($CL$)**. * **Half-life ($t_{1/2}$):** It takes approximately **4 to 5 half-lives** to reach steady-state concentration without a loading dose. * **Clinical Application:** Loading doses are essential for drugs with long half-lives (e.g., **Amiodarone, Digoxin**) or in emergencies where immediate effect is needed (e.g., **Lidocaine** in arrhythmias). * **Renal/Hepatic Impairment:** In patients with renal failure, the **Maintenance Dose** must be reduced (due to decreased clearance), but the **Loading Dose** usually remains the same unless the $V_d$ is significantly altered.

Question 15: Variation in the sensitivity of response to increasing doses of a drug in different individuals can be obtained from which type of dose-response curve?

A. Graded dose-response curve
B. Quantal dose-response curve (Correct Answer)
C. Potency
D. Efficacy

Explanation: **Explanation:** The core of this question lies in distinguishing between how an individual responds to a drug versus how a population responds. **1. Why Option B is Correct:** A **Quantal Dose-Response Curve (QDRC)** describes an "all-or-none" response (e.g., sleep/no sleep, death/survival) across a population. It plots the fraction of the population that manifests a specific effect at increasing doses. Because individuals have different genetic makeups and physiological states (**inter-individual variation**), they require different doses to achieve the same effect. The QDRC is the primary tool used to visualize this variation in sensitivity and to determine the **Therapeutic Index (TI)**. **2. Why Other Options are Incorrect:** * **A. Graded Dose-Response Curve:** This measures the intensity of a response in a **single individual** as the dose increases (e.g., the increase in heart rate with increasing doses of Adrenaline). It defines efficacy and potency but does not account for population-wide sensitivity variations. * **C. Potency:** This refers to the amount of drug (dose) required to produce an effect of a given intensity. It is determined by the $EC_{50}$ on a Graded curve. * **D. Efficacy:** This refers to the maximal response ($E_{max}$) a drug can produce, regardless of dose. **NEET-PG High-Yield Pearls:** * **Graded Curve:** Tells us about **Efficacy** (Maximal effect) and **Potency** ($EC_{50}$). * **Quantal Curve:** Tells us about **Selectivity**, **Safety**, and **Variability** ($ED_{50}$, $TD_{50}$, $LD_{50}$). * **Therapeutic Index (TI):** Calculated from the Quantal curve as $TI = LD_{50} / ED_{50}$. A higher TI indicates a safer drug. * **Standard Safety Margin:** Also derived from the Quantal curve: $[(LD_1 - ED_{99}) / ED_{99}] \times 100$.

Question 16: What is the primary purpose of pharmacovigilance?

A. To regulate pharmacy companies
B. To monitor drug potency and efficacy
C. To monitor adverse effects of drugs (Correct Answer)
D. To ensure ethical drug practices

Explanation: **Explanation:** Pharmacovigilance (PV) is defined by the WHO as the science and activities relating to the **detection, assessment, understanding, and prevention of adverse effects** or any other drug-related problems. Its primary goal is to ensure patient safety by identifying previously unrecognized adverse drug reactions (ADRs) after a drug has been released into the market (Phase IV clinical trials). **Analysis of Options:** * **Option C (Correct):** The core mandate of pharmacovigilance is the continuous monitoring of the safety profile of drugs. Since clinical trials (Phases I-III) involve limited populations, rare or long-term adverse effects are often only discovered through post-marketing surveillance. * **Option A:** Regulating pharmaceutical companies is the role of national regulatory authorities (like the CDSCO in India or the FDA in the USA), not the specific process of pharmacovigilance. * **Option B:** While efficacy is monitored during clinical trials, pharmacovigilance focuses specifically on *safety* rather than how well the drug works (efficacy) or its chemical strength (potency). * **Option D:** Ethical drug practices are governed by Bioethics committees and Good Clinical Practice (GCP) guidelines. **High-Yield Clinical Pearls for NEET-PG:** * **Phase IV Clinical Trial:** This is synonymous with post-marketing surveillance and is the stage where pharmacovigilance is most active. * **Pharmacovigilance Programme of India (PvPI):** Launched in 2010; the National Coordinating Centre is the Indian Pharmacopoeia Commission (IPC), Ghaziabad. * **Uppsala Monitoring Centre (UMC):** Located in Sweden, it is the WHO collaborating centre for international drug monitoring. * **Spontaneous Reporting:** This is the most common method used in pharmacovigilance to identify new ADRs.

Question 17: Which of the following drugs is NOT bound to alpha-1-acid glycoprotein?

A. Lignocaine
B. Tolbutamide (Correct Answer)
C. Quinidine
D. Propranolol

Explanation: ### Explanation The binding of drugs to plasma proteins is a crucial pharmacokinetic concept. In the blood, drugs primarily bind to two types of proteins: **Albumin** and **Alpha-1-acid glycoprotein (AAG)**. **1. Why Tolbutamide is the Correct Answer:** Tolbutamide is an acidic drug (Sulfonylurea). As a general rule, **acidic drugs bind primarily to Plasma Albumin**, while **basic drugs bind to Alpha-1-acid glycoprotein (AAG)**. Since Tolbutamide is acidic, it does not bind to AAG, making it the correct choice. **2. Analysis of Incorrect Options:** * **Lignocaine (Option A):** This is a basic drug (local anesthetic) and is a classic example of a drug that binds extensively to AAG. * **Quinidine (Option B):** An alkaloid and a basic drug used as an antiarrhythmic; it binds significantly to AAG. * **Propranolol (Option D):** A basic beta-blocker that shows high affinity for AAG. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **The "Acid-to-Acid" Rule:** Remember **A**cidic drugs bind to **A**lbumin (e.g., NSAIDs, Warfarin, Phenytoin, Penicillins, and Sulfonylureas like Tolbutamide). * **The "Basic-to-Glycoprotein" Rule:** **B**asic drugs bind to **A**AG (e.g., Lidocaine, Propranolol, Quinidine, Tricyclic Antidepressants, and Bupivacaine). * **Clinical Significance of AAG:** AAG is an "acute-phase reactant." Its levels increase during inflammation, infection, or malignancy. This can lead to decreased free (active) fractions of basic drugs like Lignocaine, potentially requiring dosage adjustments in such patients. * **Albumin Levels:** Conversely, albumin levels often decrease in chronic liver disease or nephrotic syndrome, leading to increased toxicity of acidic drugs like Warfarin.

Question 18: Which drug has a wide therapeutic index?

A. Digoxin
B. Lithium
C. Phenytoin
D. Penicillin (Correct Answer)

Explanation: ### Explanation **Therapeutic Index (TI)** is a quantitative measurement of a drug's safety. It is defined as the ratio of the dose that produces toxicity to the dose that produces a clinically desired effect ($TI = TD_{50} / ED_{50}$). **1. Why Penicillin is Correct:** Penicillin has a **wide therapeutic index**, meaning there is a large margin between the effective dose and the toxic dose. This is primarily because penicillin targets the bacterial cell wall (peptidoglycan synthesis), a structure that does not exist in human cells. Consequently, even very high doses are generally well-tolerated by the human body, unless the patient has a specific hypersensitivity/allergy. **2. Why the Other Options are Incorrect:** * **Digoxin (A):** A classic example of a **narrow therapeutic index** drug. It requires therapeutic drug monitoring (TDM) because the dose required to treat heart failure/arrhythmias is very close to the dose that causes life-threatening digitalis toxicity. * **Lithium (B):** Used in bipolar disorder, lithium has an extremely narrow window (therapeutic range: 0.6–1.2 mEq/L). Levels above 1.5 mEq/L can lead to severe neurotoxicity and renal impairment. * **Phenytoin (C):** This antiepileptic follows **zero-order kinetics** (saturation kinetics) at higher therapeutic concentrations. Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity (ataxia, nystagmus). **3. NEET-PG High-Yield Pearls:** * **Mnemonic for Narrow Therapeutic Index drugs:** "**W**arning, **T**hese **L**ethal **D**rugs **P**revent **C**uring" (**W**arfarin, **T**heophylline, **L**ithium, **D**igoxin, **P**henytoin/Phenobarbitone, **C**arbamazepine). * Drugs with a wide TI (e.g., Penicillin, Paracetamol, Benzodiazepines) are generally safer and do not require routine TDM. * **Low TI** = High risk of toxicity; **High TI** = Safer profile.

Question 19: What genetic variation in a drug metabolism pathway is known to cause severe toxicity with fluorouracil?

A. CYP2C9
B. Dihydropyrimidine dehydrogenase (Correct Answer)
C. Thiopurine-S methyltransferase
D. CYP2D6

Explanation: **Explanation:** **Dihydropyrimidine dehydrogenase (DPD)** is the rate-limiting enzyme responsible for the catabolism of over 80% of administered **5-Fluorouracil (5-FU)** and its oral prodrug, Capecitabine. In individuals with **DPD deficiency** (caused by mutations in the *DPYD* gene), the body cannot effectively clear the drug. This leads to an accumulation of active metabolites, resulting in severe, life-threatening toxicities such as profound myelosuppression, intractable diarrhea, neurotoxicity, and hand-foot syndrome. **Analysis of Incorrect Options:** * **CYP2C9:** This enzyme metabolizes drugs like **Warfarin**, Phenytoin, and NSAIDs. Variations lead to an increased risk of bleeding with warfarin. * **Thiopurine-S methyltransferase (TPMT):** This enzyme is responsible for the metabolism of 6-Mercaptopurine and Azathioprine. Deficiency leads to severe bone marrow toxicity when these drugs are used. * **CYP2D6:** This is a highly polymorphic enzyme involved in the metabolism of ~25% of drugs, including **Codeine** (conversion to morphine), Tamoxifen, and many antidepressants/antipsychotics. **High-Yield Clinical Pearls for NEET-PG:** * **DPD Testing:** Pre-therapeutic screening for *DPYD* variants is increasingly recommended to prevent fatal 5-FU toxicity. * **Uridine Triacetate:** This is the specific **antidote** used for 5-FU or Capecitabine overdose or early-onset severe toxicity. * **TPMT vs. DPD:** Do not confuse them; both cause chemo-toxicity, but TPMT is for thiopurines (6-MP) and DPD is for pyrimidines (5-FU).

Question 20: Which is the most appropriate definition of spare receptors?

A. Receptors that remain unoccupied even after a drug produces its maximal response. (Correct Answer)
B. Receptors involved in the binding of inverse agonists.
C. Receptors that are responsible for producing adverse drug effects.
D. Receptors that are unable to produce a maximum response.

Explanation: **Explanation:** The concept of **spare receptors** (also known as receptor reserve) is fundamental to pharmacodynamics [1]. A drug is said to have spare receptors when the **maximal biological response ($E_{max}$)** is achieved at a concentration where not all available receptors are occupied [1]. 1. **Why Option A is Correct:** In many systems, the relationship between receptor occupancy and tissue response is non-linear. Signal amplification (e.g., via G-proteins and second messengers like cAMP) allows a full agonist to trigger the maximum possible cellular effect while occupying only a small fraction (e.g., 1% to 10%) of the total receptor population [1]. The remaining unoccupied receptors are "spare." 2. **Why Other Options are Incorrect:** * **Option B:** Inverse agonists bind to the same receptor site as agonists but stabilize the inactive conformation, reducing constitutive activity. This is unrelated to the "spare" status. * **Option C:** Adverse effects are typically mediated by "off-target" binding or excessive activation of intended receptors, not specifically by spare receptors. * **Option D:** Receptors that cannot produce a maximum response even at 100% occupancy are associated with **partial agonists**, which have low intrinsic activity [1]. **High-Yield Clinical Pearls for NEET-PG:** * **EC50 vs. Kd:** In the presence of spare receptors, the **$EC_{50}$** (concentration for half-maximal response) is always **lower** than the **$K_d$** (concentration for half-maximal binding) [1]. * **Experimental Proof:** Spare receptors are demonstrated using **irreversible antagonists** [1]. If a small dose of an irreversible antagonist is added and the $E_{max}$ remains unchanged (though the curve shifts right), spare receptors exist. * **Clinical Significance:** Spare receptors increase the **sensitivity** of a cell to low concentrations of a drug, ensuring a robust physiological response even when ligand levels are low [1].

Question 21: Which of the following terms best describes a drug that blocks the action of adrenaline at its receptors by occupying those receptors without activating them?

A. Pharmacologic antagonist (Correct Answer)
B. Non-competitive antagonist
C. Physiologic antagonist
D. Chemical antagonist

Explanation: ### Explanation **1. Why Option A is Correct:** A **pharmacologic antagonist** is a drug that binds to the same receptor as an agonist (in this case, adrenaline) but does not activate it. By occupying the receptor site, it prevents the agonist from binding and exerting its effect. This is the classic definition of receptor-level blockade. Since it competes for the same binding site, it is also often referred to as a competitive antagonist. **2. Why the Other Options are Incorrect:** * **B. Non-competitive antagonist:** These drugs do not simply "occupy" the receptor site to block the agonist; they either bind irreversibly to the active site or bind to an **allosteric site**, changing the receptor's shape so the agonist cannot trigger a response. Unlike pharmacologic antagonists, their effect cannot be overcome by increasing agonist concentration. * **C. Physiologic antagonist:** This refers to two drugs acting on **different receptors** to produce opposite effects in the same system. *Example:* Histamine (bronchoconstriction via H1) vs. Adrenaline (bronchodilation via β2). * **D. Chemical antagonist:** This involves a direct chemical reaction between two substances in solution, neutralizing the drug before it reaches a receptor. *Example:* Protamine sulfate neutralizing Heparin. **3. NEET-PG High-Yield Pearls:** * **Competitive Antagonism:** Shifts the Dose-Response Curve (DRC) to the **right** (increases $EC_{50}$), but the **maximal efficacy ($E_{max}$) remains unchanged**. * **Non-competitive Antagonism:** Flattens the DRC, **decreasing the $E_{max}$**, while the $EC_{50}$ usually remains the same. * **Inverse Agonist:** Binds to the same receptor as an agonist but produces an effect **opposite** to that of the agonist (e.g., Beta-carbolines at GABA receptors).

Question 22: Which of the following drugs is not metabolized by acetylation?

A. Isoniazid
B. Hydralazine
C. Phenytoin (Correct Answer)
D. Procainamide

Explanation: **Explanation:** The correct answer is **Phenytoin**. This question tests your knowledge of **Phase II metabolism**, specifically the **Acetylation** pathway, and the clinical significance of genetic polymorphism. **1. Why Phenytoin is the correct answer:** Phenytoin is primarily metabolized in the liver via **Phase I metabolism (Oxidation)** by the cytochrome P450 enzyme system, specifically **CYP2C9** and **CYP2C19**. It does not undergo acetylation. A key clinical feature of Phenytoin is that it follows **zero-order kinetics** (capacity-limited elimination) at therapeutic or high concentrations. **2. Why the other options are incorrect:** Options A, B, and D are the classic examples of drugs metabolized by **N-acetyltransferase (NAT2)**. * **Isoniazid (INH):** The prototype drug for acetylation. Genetic polymorphism leads to "Fast Acetylators" (risk of hepatotoxicity) and "Slow Acetylators" (risk of peripheral neuropathy). * **Hydralazine:** An antihypertensive that undergoes significant first-pass acetylation. * **Procainamide:** An antiarrhythmic metabolized to N-acetylprocainamide (NAPA). **3. High-Yield Clinical Pearls for NEET-PG:** * **The "SHIP" Mnemonic:** Drugs metabolized by acetylation that can cause **Drug-Induced Lupus Erythematosus (DILE)** are **S**ulfonamides, **H**ydralazine, **I**soniazid, and **P**rocainamide. * **Slow Acetylators:** These individuals are at a higher risk of DILE and peripheral neuropathy (with INH) due to higher plasma concentrations of the parent drug. * **Fast Acetylators:** May require higher doses of these drugs to achieve therapeutic effects but are at higher risk of INH-induced hepatitis due to rapid formation of toxic metabolites.

Question 23: Which of the following statements about a placebo is true?

A. It has pharmacodynamic activity.
B. It is the active moiety of the tablet.
C. It produces the same effect in all patients.
D. It is an inert substance. (Correct Answer)

Explanation: ### Explanation **1. Why Option D is Correct:** A **placebo** (Latin for "I shall please") is defined as an **inert substance** or dummy medication that has no specific pharmacological activity against the condition being treated. It is typically composed of inactive ingredients like lactose, starch, or saline [1]. The "placebo effect" refers to the psychological or non-specific physiological improvement observed in a patient due to their expectation of healing or the act of receiving treatment, rather than the substance itself. **2. Why the Other Options are Incorrect:** * **Option A:** Placebos lack **pharmacodynamic activity** because they do not interact with specific receptors or enzymes to alter physiological functions [2]. Any observed change is psychogenic. * **Option B:** The **active moiety** is the part of a drug molecule responsible for its therapeutic effect. Since placebos are chemically inactive, they contain no active moiety. * **Option C:** The placebo effect is highly subjective and **variable**. It does not produce the same effect in all patients; factors like the patient’s personality, the doctor’s communication style, and the color/route of the placebo influence the outcome. **3. NEET-PG High-Yield Pearls:** * **Clinical Trials:** Placebos are primarily used as "controls" in Randomized Controlled Trials (RCTs) to distinguish the true pharmacologic effect of a new drug from the psychological effects of treatment [1, 3]. * **Nocebo Effect:** This is the "evil twin" of the placebo effect, where a patient experiences worsening symptoms or side effects due to negative expectations. * **Ethics:** In modern medicine, using a placebo when an effective standard treatment exists is generally considered unethical (Declaration of Helsinki).

Question 24: What is the main concern in drug designing?

A. Decreasing binding affinity of drug to target protein
B. Increasing binding affinity of drug to non-target protein
C. Increasing the number of interactions of drug with target protein (Correct Answer)
D. Decreasing the potency of the drug

Explanation: **Explanation:** In drug design, the primary objective is to create a molecule that binds specifically and strongly to its intended biological target (receptor, enzyme, or ion channel) [1]. **Why Option C is Correct:** The strength of the drug-receptor complex is determined by the **number and nature of chemical interactions** (such as hydrogen bonds, van der Waals forces, and ionic bonds) between the drug and the target protein [4]. By **increasing the number of interactions**, the binding affinity and selectivity are enhanced [1]. This ensures that the drug remains bound to the target long enough to elicit a therapeutic effect, thereby increasing **potency** and reducing the dose required [3]. **Why the other options are incorrect:** * **Option A:** Decreasing binding affinity would make the drug less effective, requiring higher doses and increasing the risk of dissociation before a response is triggered. * **Option B:** Increasing affinity for non-target proteins leads to **"off-target effects,"** which are the primary cause of drug toxicity and side effects [1]. * **Option D:** The goal of drug design is to *increase* potency (the amount of drug needed to produce an effect), not decrease it [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacogenomics** focuses on how genetic variations (SNPs) affect drug response. A change in the amino acid sequence of a target protein can alter the "number of interactions," leading to drug resistance (e.g., BCR-ABL mutations in CML). * **Structure-Activity Relationship (SAR):** The study of how modifying a drug’s chemical structure changes its biological activity [2], [3]. * **Covalent bonds** are the strongest drug-receptor interactions and are usually irreversible (e.g., Aspirin binding to COX, Phenoxybenzamine to alpha-receptors) [4].

Question 25: Botulinum toxin acts by:

A. Presynaptic release of acetylcholine
B. Presynaptic inhibition of release of acetylcholine (Correct Answer)
C. GABA mimetic
D. GABA antagonist

Explanation: **Explanation:** Botulinum toxin, produced by the bacterium *Clostridium botulinum*, is a potent neurotoxin that causes flaccid paralysis by targeting the neuromuscular junction. **Mechanism of Action (Why B is correct):** The toxin acts as a zinc-dependent endopeptidase. Once internalized into the presynaptic nerve terminal, it cleaves **SNARE proteins** (specifically SNAP-25, synaptobrevin, or syntaxin). These proteins are essential for the docking and fusion of acetylcholine-containing vesicles with the presynaptic membrane. By destroying these proteins, the toxin prevents the exocytosis of acetylcholine into the synaptic cleft, leading to **presynaptic inhibition of acetylcholine release**. **Analysis of Incorrect Options:** * **Option A:** This describes the mechanism of certain spider venoms (like Black Widow venom/α-latrotoxin), which cause massive neurotransmitter release, leading to muscle spasms. * **Options C & D:** Botulinum toxin acts specifically on cholinergic (acetylcholine) transmission at the peripheral neuromuscular junction and autonomic ganglia. It does not have a direct mechanism involving GABA, which is the primary inhibitory neurotransmitter in the Central Nervous System (CNS). **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Presentation:** Causes "Floppy Baby Syndrome" (infant botulism via honey ingestion) and symmetric descending paralysis. * **Therapeutic Uses:** Used for focal dystonias (e.g., blepharospasm, torticollis), achalasia cardia, hyperhidrosis, and cosmetic reduction of wrinkles. * **Contrast with Tetanus Toxin:** While both cleave SNARE proteins, Tetanus toxin undergoes retrograde axonal transport to the CNS and inhibits **GABA/Glycine** release from Renshaw cells, causing spastic paralysis.

Question 26: All drugs are metabolized by acetylation EXCEPT:

A. Phenytoin (Correct Answer)
B. Isoniazid
C. Procainamide
D. Hydralazine

Explanation: ### Explanation The correct answer is **Phenytoin**. **1. Underlying Medical Concept: Acetylation** Acetylation is a **Phase II metabolic reaction** catalyzed by the enzyme **N-acetyltransferase (NAT)**. This pathway is genetically determined, leading to the classification of individuals as "fast acetylators" or "slow acetylators." **Phenytoin** is primarily metabolized by **Phase I oxidation** (hydroxylation) via the cytochrome P450 system, specifically **CYP2C9** and **CYP2C19**. It does not undergo acetylation. Phenytoin also follows zero-order kinetics at high therapeutic concentrations, making its metabolism easily saturable. **2. Analysis of Incorrect Options** The other three drugs are classic examples of drugs metabolized by acetylation. A helpful mnemonic to remember these is **SHIP**: * **S**ulfonamides * **H**ydralazine (Option D) * **I**soniazid (Option B) * **P**rocainamide (Option C) **3. Clinical Pearls for NEET-PG** * **Drug-Induced Lupus Erythematosus (DILE):** Slow acetylators are at a significantly higher risk of developing DILE when taking Hydralazine, Procainamide, or Isoniazid because the drugs persist longer in the body. * **Isoniazid Toxicity:** Slow acetylators are more prone to peripheral neuropathy (due to Vitamin B6 deficiency), while fast acetylators may be more prone to isoniazid-induced hepatotoxicity (due to rapid conversion to acetyl-hydrazine). * **Genetic Polymorphism:** The NAT2 gene is the most clinically relevant polymorphic gene governing acetylation rates in humans. * **Phenytoin Side Effects:** Remember the mnemonic **HOT MALAI** (Hirsutism, Osteomalacia, Teratogenicity, Megaloblastic anemia, Ataxia, Lymphadenopathy, Arrhythmias, Insulin inhibition).

Question 27: Glucagon acts via which second messenger system?

A. cAMP (Correct Answer)
B. cGMP
C. Cytoplasmic Ca+
D. Intracellular K+

Explanation: **Explanation:** Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It exerts its primary metabolic effects by binding to specific **G Protein-Coupled Receptors (GPCRs)** on the surface of hepatocytes. 1. **Why cAMP is correct:** When glucagon binds to its receptor, it activates the **Gs (stimulatory) protein**, which in turn stimulates the enzyme **Adenylyl Cyclase**. This enzyme converts ATP into **cyclic AMP (cAMP)**. Increased levels of cAMP activate **Protein Kinase A (PKA)**, leading to the phosphorylation of key enzymes that promote glycogenolysis and gluconeogenesis while inhibiting glycogenesis. 2. **Why other options are incorrect:** * **cGMP:** This is the second messenger for Atrial Natriuretic Peptide (ANP) and Nitric Oxide (NO), primarily involved in vasodilation. * **Cytoplasmic Ca²⁺:** This is typically associated with the **Gq pathway** (via IP3/DAG), used by hormones like Oxytocin, Vasopressin (V1 receptors), and α1-adrenergic agonists. * **Intracellular K⁺:** While ion channels are involved in insulin secretion (ATP-sensitive K+ channels), they do not serve as the primary second messenger for glucagon signaling. **High-Yield Clinical Pearls for NEET-PG:** * **Glucagon in Beta-blocker Overdose:** Glucagon is the **antidote of choice** for beta-blocker poisoning. It bypasses blocked beta-receptors to increase cAMP directly in cardiac myocytes, exerting positive inotropic and chronotropic effects. * **Other cAMP users:** Remember the mnemonic "FLAT ChAMP" (FSH, LH, ACTH, TSH, CRH, hCG, ADH (V2), MSH, PTH, and Glucagon). * **Insulin vs. Glucagon:** While Glucagon uses cAMP, **Insulin** uses a **Receptor Tyrosine Kinase** pathway.

Question 28: Pharmacodynamics deals with which of the following?

A. The effect of drugs on the body. (Correct Answer)
B. The effect of the body on drugs.
C. Absorption of drugs.
D. Metabolism of drugs.

Explanation: **Explanation:** **Pharmacodynamics** is defined as the study of the biochemical and physiological effects of drugs and their mechanisms of action. In simple terms, it describes **"what the drug does to the body."** This includes drug-receptor interactions, signal transduction pathways, and the resulting therapeutic or toxic effects. **Analysis of Options:** * **Option A (Correct):** This is the literal definition of pharmacodynamics. It focuses on the drug's efficacy, potency, and physiological impact. * **Option B (Incorrect):** This describes **Pharmacokinetics**, which is the study of **"what the body does to the drug."** * **Options C & D (Incorrect):** Absorption and Metabolism are two of the four primary components of pharmacokinetics (often remembered by the acronym **ADME**: Absorption, Distribution, Metabolism, and Excretion). **NEET-PG High-Yield Pearls:** 1. **Mnemonic:** Remember **D**ynamics = **D**rug does to body; **K**inetics = Body does to drug (**K**inetics involves movement). 2. **Pharmacogenomics Connection:** While pharmacokinetics deals with how genes affect drug metabolism (e.g., CYP450 polymorphisms), **pharmacodynamic variation** involves genetic differences in drug targets, such as receptors or enzymes (e.g., VKORC1 polymorphisms affecting Warfarin sensitivity). 3. **Key Parameters:** Pharmacodynamics is measured using Dose-Response Curves (DRC), looking at parameters like $ED_{50}$ (Potency) and $E_{max}$ (Efficacy). 4. **Receptors:** Most pharmacodynamic effects are mediated through four receptor families: Ion channels, G-protein coupled receptors (GPCRs), Enzymatic receptors, and Nuclear receptors.

Question 29: Which of the following drugs can cause drug-induced lupus erythematosus, particularly in individuals with slow N-acetyltransferase activity?

A. Propranolol
B. Hydralazine (Correct Answer)
C. Digoxin
D. Captopril

Explanation: **Explanation:** The correct answer is **Hydralazine**. This question tests the concept of **Pharmacogenomics**, specifically the role of the **N-acetyltransferase (NAT2)** enzyme in drug metabolism. **1. Why Hydralazine is correct:** Hydralazine is metabolized in the liver via **Phase II Acetylation**. The population is genetically divided into "Fast Acetylators" and "Slow Acetylators." In **Slow Acetylators**, the drug remains in the systemic circulation for a longer duration at higher concentrations. This prolonged exposure promotes the formation of antinuclear antibodies (ANA), leading to **Drug-Induced Lupus Erythematosus (DILE)**. **2. Why other options are incorrect:** * **Propranolol:** A beta-blocker primarily metabolized by CYP2D6 and CYP1A2. It is not associated with DILE or NAT2 activity. * **Digoxin:** A cardiac glycoside primarily excreted unchanged by the kidneys (P-glycoprotein substrate). It does not undergo acetylation. * **Captopril:** An ACE inhibitor that contains a sulfhydryl group. While it can rarely cause skin rashes or neutropenia, it is not metabolized by NAT2 and is not a classic cause of DILE. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for DILE drugs (SHIP):** **S**ulfonamides, **H**ydralazine, **I**soniazid, **P**rocainamide. * **Procainamide** carries the highest risk of inducing DILE, but **Hydralazine** is the most frequently cited in the context of slow acetylation. * **Clinical Distinction:** Unlike systemic lupus (SLE), DILE usually spares the kidneys and CNS, and symptoms typically resolve upon drug discontinuation. * **Serological Marker:** **Anti-histone antibodies** are present in >95% of DILE cases (Highly specific). Anti-dsDNA is usually negative.

Question 30: Which of the following is most likely due to a pharmacogenetic condition?

A. Hypoglycemia by insulin
B. Tachycardia by albuterol
C. Metoclopramide induced muscle dystonia
D. Primaquine induced hemolytic anemia (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is Correct:** Primaquine-induced hemolytic anemia is a classic example of a **pharmacogenetic condition** caused by **Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency**. * **Mechanism:** G6PD is essential for maintaining the pool of reduced glutathione in RBCs, which protects them from oxidative stress. * **The Trigger:** Primaquine is an oxidizing drug. In G6PD-deficient individuals (an X-linked recessive trait), the RBCs cannot neutralize the oxidative stress caused by the drug, leading to hemoglobin denaturation (Heinz bodies) and subsequent hemolysis. **2. Why Other Options are Incorrect:** * **A. Hypoglycemia by insulin:** This is a **predictable pharmacological effect** (Type A reaction). It occurs due to an extension of the drug's therapeutic action (excessive dose or inadequate carbohydrate intake) rather than a genetic polymorphism. * **B. Tachycardia by albuterol:** This is a **side effect** resulting from the stimulation of $\beta_2$ receptors in the heart (and some $\beta_1$ cross-reactivity). It is a common, expected reaction in the general population. * **C. Metoclopramide induced muscle dystonia:** This is an **Extrapyramidal Side Effect (EPS)** due to central dopamine ($D_2$) receptor blockade. While some individuals are more sensitive, it is categorized as a known adverse drug reaction rather than a specific pharmacogenetic trait. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other drugs causing hemolysis in G6PD deficiency:** Sulfonamides, Dapsone, Nitrofurantoin, and Chloroquine. * **Succinylcholine Apnea:** Caused by a genetic deficiency of **Pseudocholinesterase** (Butyrylcholinesterase). * **Slow Acetylators (NAT2 deficiency):** Prone to peripheral neuropathy with **Isoniazid** and SLE-like syndrome with **Hydralazine/Procainamide**. * **Malignant Hyperthermia:** Linked to **RYR1 gene** mutations (Ryanodine receptor) triggered by Halothane or Succinylcholine.

Question 31: All of the following statements regarding volume of distribution are true except?

A. Half-life is usually proportional to Vd.
B. It is calculated by multiplying the half-life by log base 2. (Correct Answer)
C. Skeletal muscle relaxants generally have a low volume of distribution.
D. Drugs with high plasma protein binding tend to have a low volume of distribution.

Explanation: **Explanation** **Why Option B is Correct:** The statement is mathematically incorrect. The Volume of Distribution ($V_d$) is calculated using the formula: **$V_d = \text{Dose} / \text{Plasma Concentration}$**. The relationship involving half-life ($t_{1/2}$) is actually: **$t_{1/2} = 0.693 \times V_d / \text{Clearance (CL)}$**. While $0.693$ is the natural log of 2 ($\ln 2$), $V_d$ is not derived by simply multiplying half-life by $\log_2$. Instead, $V_d$ is a primary pharmacokinetic parameter determined by the physical properties of the drug and the body, whereas half-life is a secondary parameter derived from $V_d$ and Clearance. **Analysis of Other Options:** * **Option A:** True. Since $t_{1/2} \propto V_d$, a larger volume of distribution (meaning the drug is sequestered in tissues) results in a longer half-life because the drug is less available for elimination by the liver or kidneys. * **Option C:** True. Skeletal muscle relaxants (e.g., Atracurium, Succinylcholine) are highly ionized, polar molecules. They do not cross cell membranes easily and remain largely confined to the extracellular fluid/plasma, resulting in a low $V_d$. * **Option D:** True. Drugs that bind extensively to plasma albumin (e.g., Warfarin) stay within the vascular compartment. Since $V_d = \text{Amount in body} / \text{Plasma concentration}$, a high plasma concentration leads to a low $V_d$. **High-Yield Clinical Pearls for NEET-PG:** * **Loading Dose:** $V_d$ is the primary determinant of the loading dose ($\text{LD} = V_d \times \text{Target Plasma Concentration}$). * **Hemodialysis:** Drugs with a very high $V_d$ (e.g., Digoxin, Chloroquine, TCAs) cannot be effectively removed by hemodialysis because they reside mostly in tissues, not the blood. * **Total Body Water:** If $V_d$ exceeds the total body water (~42L), it indicates the drug is highly sequestered in specific tissues (like fat or bone).

Question 32: Pharmacovigilance is a branch of pharmacology concerned with:

A. Monitoring of drugs
B. Adverse effects of drugs (Correct Answer)
C. Drug dosing
D. Drug clearance

Explanation: **Explanation:** **Pharmacovigilance (PV)** is defined by the World Health Organization (WHO) as the science and activities relating to the **detection, assessment, understanding, and prevention of adverse effects** or any other drug-related problems. Its primary goal is to ensure patient safety by identifying previously unrecognized adverse drug reactions (ADRs) after a drug has been released into the market (Phase IV clinical trials) [1]. * **Why Option B is correct:** The core mandate of pharmacovigilance is the systematic monitoring of **adverse effects**. It involves the collection of data regarding ADRs to determine the risk-benefit ratio of medications in the general population [2]. This system provides early warning signals of unexpected adverse effects that can then be investigated [1]. * **Why Option A is incorrect:** While "monitoring" is part of the process, it is too vague. Pharmacovigilance specifically monitors *safety outcomes* rather than therapeutic drug monitoring (TDM) or general drug usage patterns. * **Why Options C & D are incorrect:** Drug dosing and clearance are components of **Pharmacokinetics** (what the body does to the drug). While dosing may be adjusted based on PV data, these terms describe the physiological handling of a drug rather than the surveillance of its safety profile [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Phase IV Clinical Trials:** Pharmacovigilance is synonymous with Post-Marketing Surveillance [1]. * **Uppsala Monitoring Centre (UMC):** Located in Sweden, it is the international headquarters for global ADR monitoring. * **Pharmacovigilance Programme of India (PvPI):** The national coordination center is the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. * **Vigiflow:** The software used for reporting ADRs in India. * **Spontaneous Reporting:** The most common method used in pharmacovigilance for identifying rare or delayed adverse effects [1].

Question 33: Therapeutic drug monitoring of plasma concentrations of antihypertensive drugs is not practiced because:

A. Determination of plasma level of these drugs is a tedious and long process.
B. It is easier to measure the therapeutic effect of these drugs. (Correct Answer)
C. The antihypertensive effect does not increase linearly with the dose.
D. All antihypertensive drugs are prodrugs.

Explanation: ### Explanation **1. Why Option B is Correct:** The primary goal of Therapeutic Drug Monitoring (TDM) is to guide dosage when the clinical effect is difficult to measure or when there is a narrow therapeutic index. For antihypertensive drugs, the therapeutic effect—**blood pressure (BP)**—is an easily measurable, objective, and non-invasive clinical endpoint. Since a physician can directly titrate the dose based on a sphygmomanometer reading to achieve the target BP, measuring plasma concentrations is unnecessary, expensive, and redundant. **2. Analysis of Incorrect Options:** * **Option A:** While some assays are complex, modern chromatography (HPLC/LC-MS) makes measuring drug levels routine. The lack of TDM is due to clinical irrelevance, not technical difficulty. * **Option B:** This is the standard pharmacological principle: if a "surrogate marker" or "clinical effect" is easily quantifiable (e.g., BP for hypertension, INR for warfarin, Blood Glucose for insulin), TDM is not required. * **Option C:** While some drugs show non-linear kinetics, this would actually be an *indication* for TDM, not a reason to avoid it. * **Option D:** Only a few antihypertensives are prodrugs (e.g., Enalapril, Ramipril, Methyldopa). Most (e.g., Amlodipine, Atenolol) are active drugs. **3. NEET-PG High-Yield Pearls:** * **Indications for TDM:** Narrow therapeutic index (Lithium, Digoxin, Theophylline), lack of easily measurable clinical effect (Antiepileptics, Antipsychotics), or suspected toxicity/non-compliance. * **Exceptions to TDM:** Do not perform TDM if the clinical effect is easily measured (BP for antihypertensives, Blood sugar for Antidiabetics, INR for Warfarin). * **Key Concept:** TDM is most useful when there is a strong correlation between plasma concentration and clinical effect, but a poor correlation between dose and plasma concentration.

Question 34: Which antitubercular drug metabolism is under genetic control?

A. Rifampicin
B. Isoniazid (Correct Answer)
C. Cyclosporine
D. Pyrazinamide

Explanation: **Explanation:** The correct answer is **Isoniazid (INH)**. Its metabolism is a classic example of pharmacogenetics, specifically involving the **N-acetyltransferase 2 (NAT2)** enzyme in the liver. **1. Why Isoniazid is Correct:** Isoniazid is metabolized via **acetylation**. Due to genetic polymorphism in the *NAT2* gene, individuals are categorized into two phenotypes: * **Fast Acetylators:** They metabolize the drug quickly, leading to lower plasma levels and a higher risk of **treatment failure** or sub-therapeutic responses. * **Slow Acetylators:** They metabolize the drug slowly, leading to higher plasma levels and an increased risk of **peripheral neuropathy** (due to Vitamin B6 deficiency) and drug-induced lupus. **2. Why other options are incorrect:** * **Rifampicin:** It is primarily metabolized by deacetylation and is a potent inducer of CYP450 enzymes, but its metabolism is not significantly dictated by a specific genetic polymorphism like INH. * **Cyclosporine:** This is an immunosuppressant (not an antitubercular drug) metabolized by CYP3A4. While CYP3A4 has variations, it is not the classic example of genetic control in the context of TB therapy. * **Pyrazinamide:** It is converted to pyrazinoic acid by the enzyme pyrazinamidase. While resistance can occur due to bacterial gene mutations (*pncA*), its human metabolism is not a major focus of clinical pharmacogenetics. **High-Yield Clinical Pearls for NEET-PG:** * **Acetylation** also affects the metabolism of **Hydralazine, Procainamide, and Sulfonamides** (Mnemonic: **SHIP** - Sulfonamides, Hydralazine, Isoniazid, Procainamide). * **Slow acetylators** are more prone to **Drug-Induced Lupus Erythematosus (DILE)**. * To prevent peripheral neuropathy in slow acetylators taking INH, always co-administer **Pyridoxine (Vitamin B6)** at 10–50 mg/day.

Question 35: Pharmacogenetics is associated with:

A. Variability of enzyme action
B. Individual variability in oral absorption
C. Different dose-response relationships in different individuals
D. All of these (Correct Answer)

Explanation: **Explanation:** **Pharmacogenetics** is the study of how genetic variations (polymorphisms) influence an individual’s response to drugs [1]. It encompasses both **pharmacokinetics** (what the body does to the drug) and **pharmacodynamics** (what the drug does to the body). 1. **Variability of enzyme action (Option A):** This is the most classic example of pharmacogenetics [2]. Genetic polymorphisms in Phase I (e.g., CYP2D6, CYP2C19) and Phase II (e.g., NAT2, TPMT) enzymes lead to "fast" or "slow" metabolizer phenotypes, significantly altering drug levels [1]. 2. **Individual variability in oral absorption (Option B):** Genetic variations in drug transporters, such as **P-glycoprotein (MDR1)** or Organic Anion Transporting Polypeptides (OATPs) in the gut epithelium, dictate how much of a drug enters the systemic circulation [1]. 3. **Different dose-response relationships (Option C):** This refers to pharmacodynamic variability. Mutations in drug targets (receptors, ion channels, or enzymes) can change a drug’s affinity or efficacy. For example, polymorphisms in the **VKORC1** gene alter the sensitivity to Warfarin, requiring different doses to achieve the same anticoagulant effect. Since genetic factors influence absorption, metabolism, and receptor sensitivity, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Slow Acetylators (NAT2 deficiency):** Prone to peripheral neuropathy with **Isoniazid** and drug-induced Lupus with **Hydralazine/Procainamide** [1]. * **Pseudocholinesterase deficiency:** Leads to prolonged apnea after **Succinylcholine** administration. * **TPMT deficiency:** Increases the risk of life-threatening bone marrow suppression with **6-Mercaptopurine** and **Azathioprine**. * **HLA-B*1502:** Strongly associated with Stevens-Johnson Syndrome (SJS) in patients taking **Carbamazepine**.

Question 36: Therapeutic index of a drug is a measure of its?

A. Safety (Correct Answer)
B. Efficacy
C. Potency
D. Selectivity

Explanation: ### Explanation **1. Why "Safety" is Correct:** The **Therapeutic Index (TI)** is a quantitative measurement of the relative safety of a drug. It represents the ratio between the dose that causes toxicity and the dose that produces the desired therapeutic effect. Mathematically, it is expressed as: **TI = TD₅₀ / ED₅₀** (or LD₅₀ / ED₅₀ in animal studies) * **TD₅₀:** Dose that produces a toxic effect in 50% of the population. * **ED₅₀:** Dose that produces a therapeutic effect in 50% of the population. A **higher TI** indicates a wider "margin of safety," meaning there is a large gap between the effective dose and the toxic dose (e.g., Penicillin). A **lower TI** indicates a narrow margin of safety, requiring precise dosing and frequent monitoring (e.g., Lithium, Digoxin). **2. Why Other Options are Incorrect:** * **B. Efficacy:** Refers to the maximum response (Emax) a drug can produce, regardless of dose. It is a measure of a drug's effectiveness, not safety. * **C. Potency:** Refers to the amount of drug (dose) required to produce an effect of a given intensity (usually measured by EC₅₀). A more potent drug requires a smaller dose but is not necessarily safer. * **D. Selectivity:** Refers to a drug’s ability to affect a particular receptor or target without affecting others. While related to side effects, it is not the formal definition of the Therapeutic Index. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drugs with Narrow Therapeutic Index (Mnemonic: "Warning! Death Is Likely"):** **W**arfarin, **D**igoxin, **I**nsulin, **L**ithium. Also include Theophylline, Phenytoin, and Aminoglycosides. * **Therapeutic Window:** The range of drug concentrations in which a probability of efficacy is high and the probability of toxicity is low. * **Certain Safety Factor:** A more rigorous index calculated as **LD₁ / ED₉₉**. It ensures that the dose effective for almost everyone is still safe for the most sensitive individual.

Question 37: A partial agonist has:

A. High affinity but low intrinsic activity (Correct Answer)
B. High affinity but no intrinsic activity
C. Low affinity but high intrinsic activity
D. Low affinity and low intrinsic activity

Explanation: ### Explanation To understand this concept, we must distinguish between **Affinity** (the ability of a drug to bind to a receptor) and **Intrinsic Activity/Efficacy** (the ability of a drug to activate the receptor and produce a biological response). **1. Why Option A is Correct:** A **Partial Agonist** is a drug that binds to a receptor (High Affinity) but produces a sub-maximal response even when all receptors are occupied (Low Intrinsic Activity). On a scale of 0 to 1, the intrinsic activity of a partial agonist is between **0 and 1**. Because it competes for the same site as a full agonist but produces a weaker response, it can act as a **functional antagonist** in the presence of a full agonist. **2. Why Other Options are Incorrect:** * **Option B (High affinity, no intrinsic activity):** This describes a **Competitive Antagonist**. It binds to the receptor but has an intrinsic activity of **0**, producing no response on its own. * **Option C & D (Low affinity):** Affinity determines the potency of a drug, not its classification as an agonist or antagonist. A drug can have low affinity and still be a full agonist if it produces a maximal response once bound. **3. NEET-PG High-Yield Clinical Pearls:** * **Intrinsic Activity Values:** Full Agonist = 1; Partial Agonist = 0 to 1; Antagonist = 0; Inverse Agonist = -1. * **Clinical Examples:** * **Pindolol:** A partial agonist at $\beta$-receptors; used in hypertension to prevent excessive bradycardia. * **Buprenorphine:** A partial $\mu$-opioid agonist used in opioid withdrawal; it has a "ceiling effect" on respiratory depression. * **Varenicline:** A partial agonist at nicotinic receptors used for smoking cessation. * **Aripiprazole:** A partial D2 agonist used in schizophrenia.

Question 38: The study of how variation in the human genome affects the response to medications is known as?

A. Pharmacogenomics (Correct Answer)
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacovigilance

Explanation: **Explanation:** **Pharmacogenomics** is the study of how an individual’s entire genetic makeup (genome) influences their response to drugs. It combines pharmacology and genomics to analyze how genetic variations (such as Single Nucleotide Polymorphisms or SNPs) affect drug efficacy and toxicity. By understanding these variations, clinicians can move toward "personalized medicine," tailoring drug selection and dosages to a patient’s specific genetic profile. **Analysis of Incorrect Options:** * **Pharmacokinetics (B):** This refers to what the body does to the drug. It involves the processes of Absorption, Distribution, Metabolism, and Excretion (ADME). * **Pharmacotherapeutics (C):** This is the clinical application of drugs to prevent, diagnose, or treat diseases. It focuses on the use of drugs in the treatment of specific conditions. * **Pharmacovigilance (D):** This is the science relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems (post-marketing surveillance). **High-Yield Clinical Pearls for NEET-PG:** * **HLA-B*1502:** Screening is mandatory before starting **Carbamazepine** in Asian populations to prevent Stevens-Johnson Syndrome (SJS). * **TPMT (Thiopurine Methyltransferase):** Deficiency leads to severe bone marrow toxicity when treated with **6-Mercaptopurine** or Azathioprine. * **CYP2C19:** Polymorphism affects the activation of the prodrug **Clopidogrel**; "poor metabolizers" are at risk of cardiovascular events. * **VKORC1 & CYP2C9:** Variations in these genes significantly influence the required maintenance dose of **Warfarin**.

Question 39: Which of the following conditions is most likely due to a pharmacogenetic cause?

A. Hypoglycemia caused by insulin
B. Tachycardia caused by albuterol
C. Metoclopramide-induced muscle dystonia
D. Primaquine-induced hemolytic anemia (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is Correct:** Primaquine-induced hemolytic anemia is a classic example of a **pharmacogenetic disorder** caused by **Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency**. G6PD is an enzyme essential for maintaining the levels of reduced glutathione in red blood cells (RBCs), which protects them from oxidative stress. Primaquine is an oxidizing drug; in G6PD-deficient individuals, the RBCs cannot neutralize the oxidative stress, leading to hemoglobin denaturation (Heinz bodies) and subsequent hemolysis. This is an X-linked recessive trait, making it a genetically determined abnormal response to a drug. **2. Why Other Options are Incorrect:** * **Option A & B:** Hypoglycemia from insulin and tachycardia from albuterol are **Type A (Augmented)** adverse drug reactions. These are predictable, dose-dependent extensions of the drug’s primary pharmacological action and occur in most individuals if the dose is high enough. * **Option C:** Metoclopramide-induced muscle dystonia is an **Extrapyramidal Side Effect (EPS)** due to central dopamine (D2) receptor blockade. While some individuals are more sensitive, it is generally considered a predictable side effect of the drug's mechanism rather than a specific genetic polymorphism. **3. Clinical Pearls for NEET-PG:** * **Other drugs causing hemolysis in G6PD deficiency:** Sulfonamides, Dapsone, Nitrofurantoin, and Chloroquine. * **Succinylcholine Apnea:** Caused by a genetic deficiency of **Pseudocholinesterase** (Butyrylcholinesterase). * **Slow Acetylators (NAT2 polymorphism):** Increased risk of peripheral neuropathy with **Isoniazid** and SLE-like syndrome with **Hydralazine/Procainamide**. * **Malignant Hyperthermia:** Genetic mutation in **Ryanodine receptors (RyR1)** triggered by Halothane or Succinylcholine.

Question 40: What does the potency of a drug refer to?

A. Affinity of drug to bind to a receptor
B. Affinity of drug that binds to receptors and activates it
C. The dose required to produce a specific response (Correct Answer)
D. The maximum response a drug can produce

Explanation: **Potency** refers to the amount or **dose** of a drug required to produce an effect of a given intensity. On a Dose-Response Curve (DRC), potency is represented by the position of the curve along the x-axis (dose) [4]. A drug that produces the same effect at a lower dose is considered "more potent" [2]. **Analysis of Options:** * **Option C (Correct):** Potency is mathematically expressed as the **$EC_{50}$** (the concentration required to produce 50% of the maximum response) [1, 3]. The lower the $EC_{50}$, the higher the potency. * **Option A (Incorrect):** This describes **Affinity**, which is the tendency of a drug to bind to its receptor. While affinity influences potency, they are not synonymous. * **Option B (Incorrect):** This describes **Intrinsic Activity** (Efficacy). It is the ability of a drug to trigger a pharmacological response after binding to the receptor. * **Option D (Incorrect):** This describes **Efficacy** ($E_{max}$). Efficacy is the maximal clinical response a drug can achieve. In clinical practice, efficacy is generally more important than potency. **NEET-PG High-Yield Pearls:** 1. **Potency vs. Efficacy:** On a graph, a shift to the **left** indicates increased potency. A shift **upwards** indicates increased efficacy. 2. **Clinical Relevance:** Potency is rarely a decisive factor in drug choice; it only determines the milligram weight of the tablet [2]. For example, 5mg of Amlodipine is more potent than 50mg of Atenolol, but they are used for different clinical indications [2]. 3. **Relative Potency:** If Drug A produces a response at 10mg and Drug B produces the same response at 100mg, Drug A is 10 times more potent than Drug B [2].

Question 41: Which of the following statements is false?

A. Lipid-soluble drugs tend to have a higher volume of distribution.
B. The volume of distribution is reduced by high plasma protein binding.
C. Loading dose is equal to the volume of distribution multiplied by the target plasma concentration. (Correct Answer)
D. Half-life is constant in first-order kinetics.

Explanation: ### Explanation This question tests the fundamental principles of pharmacokinetics. The statement in **Option C** is technically incomplete and considered "false" in a clinical context because it ignores **bioavailability (F)**. #### 1. Why Option C is the Correct Answer (False Statement) The formula for **Loading Dose (LD)** is: $$LD = \frac{V_d \times C_p}{F}$$ Where $V_d$ is the Volume of Distribution, $C_p$ is the Target Plasma Concentration, and $F$ is Bioavailability. For intravenous drugs, $F = 1$, making the statement true. However, for any other route (like oral), the dose must be adjusted for bioavailability. Without specifying the route, the general formula must include $F$. #### 2. Analysis of Other Options * **Option A (True):** Lipid-soluble drugs easily cross biological membranes and distribute into adipose tissue and intracellular compartments, leading to a **high $V_d$** (e.g., Chloroquine). * **Option B (True):** Drugs that are highly bound to plasma proteins (like albumin) remain confined to the vascular compartment. This results in a **low $V_d$**. * **Option D (True):** In **First-order kinetics**, a constant *fraction* of the drug is eliminated per unit time. Therefore, the **half-life ($t_{1/2}$)** remains constant regardless of the plasma concentration. #### 3. High-Yield NEET-PG Pearls * **Maintenance Dose (MD):** Calculated using **Clearance (CL)**: $MD = \frac{CL \times C_{ss} \times \tau}{F}$ (where $\tau$ is the dosing interval). * **Zero-order Kinetics:** Half-life is **not** constant; it depends on the concentration (e.g., Ethanol, Phenytoin, Aspirin at high doses). * **Volume of Distribution:** It is a theoretical volume, not a physical one. If $V_d$ exceeds total body water (~42L), it indicates the drug is sequestered in tissues.

Question 42: Which of the following drugs acts on -2 receptors?

A. Phenylephrine
B. Midodrine
C. Clonidine (Correct Answer)
D. Methoxamine

Explanation: **Explanation:** The question tests your knowledge of sympathomimetic and sympatholytic drugs and their receptor selectivity. **Correct Answer: C. Clonidine** Clonidine is a prototypical **selective $\alpha_2$-adrenergic agonist**. It acts primarily on presynaptic $\alpha_2$ receptors in the vasomotor center of the medulla. Activation of these receptors inhibits the release of norepinephrine, leading to a decrease in sympathetic outflow to the heart and peripheral vasculature. This results in a reduction in blood pressure, making it a centrally acting antihypertensive. **Analysis of Incorrect Options:** * **A. Phenylephrine:** This is a selective **$\alpha_1$-agonist**. It is commonly used as a nasal decongestant and a vasopressor to increase blood pressure without affecting the heart rate directly (though it may cause reflex bradycardia). * **B. Midodrine:** This is an orally active **$\alpha_1$-agonist** (a prodrug converted to desglymidodrine). It is primarily used in the treatment of symptomatic orthostatic hypotension. * **D. Methoxamine:** This is another selective **$\alpha_1$-agonist** used primarily as a vasopressor to treat hypotension during anesthesia. **High-Yield Clinical Pearls for NEET-PG:** * **$\alpha_2$ Agonists:** Apart from Clonidine, other important $\alpha_2$ agonists include **Methyldopa** (drug of choice for hypertension in pregnancy), **Dexmedetomidine** (used for sedation in ICUs), and **Tizanidine** (a central muscle relaxant). * **Clonidine Withdrawal:** Abrupt cessation of clonidine can lead to a "rebound hypertensive crisis" due to a sudden surge in catecholamines. * **Diagnostic Use:** The **Clonidine Suppression Test** is used in the diagnosis of Pheochromocytoma (clonidine fails to suppress catecholamine levels in affected patients).

Question 43: Atrial Natriuretic Peptide receptors belong to which of the following types of receptors?

A. G-protein coupled receptors
B. Ligand-gated guanylyl cyclase receptor (Correct Answer)
C. Tyrosine kinase receptors
D. JAK-STAT receptors

Explanation: **Explanation:** **Atrial Natriuretic Peptide (ANP)** and Brain Natriuretic Peptide (BNP) exert their physiological effects by binding to **Natriuretic Peptide Receptor-A (NPR-A)**. This receptor is a classic example of a **transmembrane (membrane-bound) Guanylyl Cyclase**. When ANP binds to the extracellular domain, it directly activates the intracellular catalytic domain of the receptor, which converts GTP into **cyclic GMP (cGMP)**. cGMP then activates Protein Kinase G (PKG), leading to vasodilation and natriuresis. This is distinct from soluble guanylyl cyclase, which is activated by Nitric Oxide. **Analysis of Incorrect Options:** * **A. G-protein coupled receptors (GPCRs):** These utilize secondary messengers like cAMP or $IP_3/DAG$. While many hormones use GPCRs, ANP does not. * **C. Tyrosine kinase receptors:** These (e.g., Insulin, EGF) involve autophosphorylation of tyrosine residues. ANP receptors lack tyrosine kinase activity. * **D. JAK-STAT receptors:** These are used by cytokines and Growth Hormone. They do not have intrinsic enzymatic activity but recruit cytosolic Janus Kinases (JAKs). **High-Yield Clinical Pearls for NEET-PG:** 1. **Dual Role:** ANP receptors are both the receptor and the enzyme (Guanylyl Cyclase). 2. **Sacubitril:** A Neprilysin inhibitor used in Heart Failure (ARNI) that prevents the degradation of ANP/BNP, thereby increasing cGMP levels. 3. **Nesiritide:** A recombinant form of BNP used in acute decompensated heart failure, acting via this same cGMP pathway. 4. **Other cGMP-linked drugs:** Sildenafil (PDE-5 inhibitor) prevents the breakdown of the cGMP generated by these pathways.

Question 44: Which of the following is NOT an example of chronic adverse drug reactions?

A. Nitrate induced headache (Correct Answer)
B. Glucocorticoid induced osteoporosis
C. Chloroquine induced retinopathy
D. Amiodarone deposition in cornea

Explanation: ### Explanation Adverse Drug Reactions (ADRs) are classified using the **Rawlins and Thompson classification**. To answer this question, one must distinguish between **Type A (Augmented)** and **Type C (Chronic)** reactions. **1. Why "Nitrate induced headache" is the correct answer:** Nitrate-induced headache is a **Type A (Augmented)** reaction. It is a predictable, dose-dependent extension of the drug’s primary pharmacological action (vasodilation). It occurs acutely shortly after administration. Because it is an immediate effect rather than a result of long-term cumulative exposure, it is NOT classified as a chronic ADR. **2. Analysis of Incorrect Options (Chronic ADRs):** Type C reactions are associated with **long-term drug use** and involve cumulative dose effects. * **Glucocorticoid-induced osteoporosis:** This occurs due to the cumulative suppression of osteoblast activity and calcium resorption over months or years of therapy. * **Chloroquine-induced retinopathy:** This is a classic example of cumulative toxicity where the drug deposits in the retinal pigment epithelium over a long duration (typically seen with high cumulative doses >1000g). * **Amiodarone deposition in cornea:** Also known as *cornea verticillata*, this occurs due to the long-term accumulation of the drug in lysosomal compartments (phospholipidosis). **3. High-Yield Clinical Pearls for NEET-PG:** * **Type A (Augmented):** Common, predictable, low mortality (e.g., Gastritis by NSAIDs, Hypoglycemia by Insulin). * **Type B (Bizarre):** Unpredictable, idiosyncratic, high mortality (e.g., Anaphylaxis, SJS/TEN). * **Type C (Chronic):** Related to cumulative dose (e.g., Analgesic nephropathy). * **Type D (Delayed):** Occurs years after treatment (e.g., Teratogenicity, Carcinogenicity). * **Type E (End of use):** Withdrawal symptoms (e.g., Opioid withdrawal, Rebound hypertension with Clonidine).

Question 45: The study of how variations in the human genome affect the response to medications is known as?

A. Pharmacogenomics (Correct Answer)
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacovigilance

Explanation: **Explanation:** **Pharmacogenomics** is the study of how an individual’s entire genetic makeup (genome) influences their response to drugs. It combines pharmacology and genomics to analyze how genetic variations (like Single Nucleotide Polymorphisms or SNPs) affect drug metabolism, efficacy, and toxicity. This field is the cornerstone of **personalized medicine**, allowing clinicians to prescribe the "right drug at the right dose" based on a patient's genotype. **Analysis of Incorrect Options:** * **Pharmacokinetics (B):** Refers to what the body does to the drug. it involves the processes of Absorption, Distribution, Metabolism, and Excretion (ADME). * **Pharmacotherapeutics (C):** The clinical application of drugs to prevent, treat, or diagnose diseases. It focuses on the use of pharmacological information for patient care. * **Pharmacovigilance (D):** The science relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems (post-marketing surveillance). **High-Yield Clinical Pearls for NEET-PG:** * **HLA-B*1502:** Screening is mandatory before starting **Carbamazepine** in patients of Asian ancestry to prevent Stevens-Johnson Syndrome (SJS). * **TPMT (Thiopurine Methyltransferase):** Deficiency leads to life-threatening bone marrow suppression when treated with **6-Mercaptopurine** or Azathioprine. * **CYP2C19:** Polymorphisms affect the activation of **Clopidogrel** (a prodrug); "poor metabolizers" have a higher risk of cardiovascular events. * **VKORC1 & CYP2C9:** Variations in these genes significantly influence the required maintenance dose of **Warfarin**.

Question 46: What is the approximate dose of a drug for a 3-year-old child compared to an adult dose?

A. Same as an adult dose
B. Half of an adult dose
C. One-third of an adult dose (Correct Answer)
D. One-fourth of an adult dose

Explanation: ### Explanation The correct answer is **C. One-third of an adult dose.** Pediatric drug dosing is not merely a reduction of adult doses; it is based on physiological differences in body surface area (BSA), weight, and metabolic maturity. To estimate pediatric doses when specific guidelines are unavailable, several mathematical formulas are used. **The Underlying Concept: Young’s Rule** For children aged 1–12 years, **Young’s Rule** is a classic high-yield formula used to calculate the dose [1]: * **Formula:** $\text{Child Dose} = \frac{\text{Age}}{\text{Age} + 12} \times \text{Adult Dose}$ * **Calculation for a 3-year-old:** $\frac{3}{3 + 12} = \frac{3}{15} = \frac{1}{5}$ of an adult dose. However, clinical practice and more accurate indices like **Clark’s Rule** (based on weight) [1] or **BSA-based calculations** (the most accurate method) generally place the requirement for a 3-year-old (average weight 14–15 kg) at approximately **one-third (30-33%)** of the adult dose to account for their higher metabolic rate and larger BSA relative to weight compared to adults. **Analysis of Incorrect Options:** * **A. Same as an adult dose:** Incorrect. Children have immature hepatic enzymes and renal clearance [2]; an adult dose would lead to severe toxicity. * **B. Half of an adult dose:** Incorrect. This typically applies to older children/adolescents (around 12 years or 40 kg). * **D. One-fourth of an adult dose:** Incorrect. This is more characteristic of an infant (approx. 1 year old). **High-Yield Clinical Pearls for NEET-PG:** 1. **Most Accurate Method:** Body Surface Area (BSA) is the most reliable method for pediatric dosing ($ \frac{\text{Child's BSA}}{\text{Adult BSA (1.73 } m^2)} \times \text{Adult Dose}$). 2. **Dilling’s Rule:** $\frac{\text{Age}}{20} \times \text{Adult Dose}$ (Easier for quick estimation). 3. **Fried’s Rule:** Used for infants (<1 year): $\frac{\text{Age in months}}{150} \times \text{Adult Dose}$. 4. **Physiological Note:** Neonates have higher total body water and lower plasma protein binding, significantly altering the Volume of Distribution ($V_d$) of drugs.

Question 47: In sub-acute toxicity studies, for what duration is the drug given to animals?

A. A single dose
B. 2-12 weeks (Correct Answer)
C. 6-12 months
D. 1-3 years

Explanation: **Explanation:** Toxicity studies are a fundamental part of preclinical drug development, categorized based on the duration of drug administration to determine the safety profile of a new chemical entity. **1. Why Option B is Correct:** **Sub-acute toxicity studies** (also known as repeated-dose or short-term toxicity studies) involve the daily administration of a drug for a period typically ranging from **2 to 12 weeks** (commonly 4 weeks/28 days). The primary objective is to identify target organ toxicity and establish the "No Observed Adverse Effect Level" (NOAEL) before proceeding to human clinical trials. **2. Analysis of Incorrect Options:** * **Option A (Single dose):** This refers to **Acute Toxicity studies**. The drug is administered in a single dose (or multiple doses within 24 hours) to determine the Median Lethal Dose ($LD_{50}$) and immediate toxic effects. * **Option C (6-12 months):** This refers to **Chronic Toxicity studies**. These are conducted to evaluate the effects of long-term exposure, including cumulative toxicity and potential carcinogenic effects. In most species, this lasts 6 months, though it can extend to 12. * **Option D (1-3 years):** This duration is typically reserved for **Carcinogenicity studies** in rodents (usually 2 years) or long-term observation in specific longitudinal safety models. **High-Yield Clinical Pearls for NEET-PG:** * **Acute Toxicity:** Single dose; determines $LD_{50}$. * **Sub-acute Toxicity:** 2–12 weeks; identifies target organs of toxicity. * **Chronic Toxicity:** >6 months; evaluates cumulative effects. * **Therapeutic Index (TI):** Calculated as $LD_{50} / ED_{50}$. A higher TI indicates a safer drug. * **Pre-clinical requirement:** Toxicity must be tested in at least two mammalian species (one rodent and one non-rodent) before Phase I trials.

Question 48: Administration of which of the following drugs requires therapeutic drug monitoring?

A. Lithium (Correct Answer)
B. Haloperidol
C. Diazepam
D. Acetazolamide

Explanation: ### Explanation **Therapeutic Drug Monitoring (TDM)** is indicated for drugs with a **narrow therapeutic index**, where the difference between the therapeutic and toxic dose is minimal, and there is a direct correlation between plasma concentration and clinical effect. **1. Why Lithium is the Correct Answer:** Lithium is the classic example of a drug requiring TDM. It has a very narrow therapeutic range (typically **0.6–1.2 mEq/L**). Concentrations slightly above this range can lead to severe toxicity (tremors, ataxia, seizures), while levels below it are ineffective for treating bipolar disorder. Furthermore, its pharmacokinetics are highly variable based on renal function and salt intake, making regular monitoring of serum levels mandatory for safety and efficacy. **2. Why the Other Options are Incorrect:** * **Haloperidol (Antipsychotic):** While it has side effects (EPS), its therapeutic window is relatively wide. Clinical response (reduction in psychosis) is used to titrate the dose rather than plasma levels. * **Diazepam (Benzodiazepine):** It has a high therapeutic index. Monitoring is unnecessary because the dose required to cause fatal toxicity is extremely high compared to the sedative dose. * **Acetazolamide (Carbonic Anhydrase Inhibitor):** Used for glaucoma or altitude sickness, its effect is monitored clinically (intraocular pressure) or via biochemical markers (acid-base balance), not plasma drug levels. **Clinical Pearls for NEET-PG:** * **Mnemonic for TDM drugs:** "**L**earn **T**he **P**harmacology **D**ose **V**ery **C**arefully" (**L**ithium, **T**ricyclic Antidepressants/Theophylline, **P**henytoin, **D**igoxin, **V**alproate, **C**yclosporine). * **Lithium Sampling Time:** Blood for TDM should be drawn **12 hours after the last dose** (trough level). * **Excretion:** Lithium is handled by the kidneys like sodium; thus, **thiazide diuretics** and **NSAIDs** can increase lithium levels and cause toxicity.

Question 49: What are orphan drugs?

A. Drugs that are commercially easy to obtain
B. Drugs used to treat rare diseases (Correct Answer)
C. Drugs developed with the primary intention of monetary gain
D. All of the above

Explanation: **Explanation:** **Orphan drugs** are medicinal products intended for the diagnosis, prevention, or treatment of **rare diseases** (orphan diseases). These conditions affect a small percentage of the population (e.g., in the US, fewer than 200,000 people; in India, diseases with a prevalence of less than 1 in 5,000). Because the patient base is so small, pharmaceutical companies are often reluctant to develop them under normal market conditions, as the cost of research and development would not be recovered through sales. **Analysis of Options:** * **Option B (Correct):** This aligns with the definition. To encourage the development of these drugs, governments provide incentives like tax credits, clinical research subsidies, and extended patent exclusivity (e.g., 7 years in the US). * **Option A (Incorrect):** Orphan drugs are often difficult to obtain and extremely expensive due to limited production and specialized distribution. * **Option C (Incorrect):** These drugs are developed despite a lack of primary monetary gain. They are "orphaned" because they lack commercial viability without government intervention. **High-Yield Clinical Pearls for NEET-PG:** * **Examples of Orphan Drugs:** Digoxin Immune Fab (for digitalis toxicity), Fomepizole (for methanol poisoning), Thalidomide (for leprosy/multiple myeloma), and various enzyme replacements for storage disorders (e.g., Alglucerase for Gaucher’s disease). * **Orphan Status:** A drug can be "orphan" in one country but not another, depending on the local prevalence of the disease. * **The Orphan Drug Act (1983):** The landmark legislation in the US that pioneered the concept of providing regulatory and financial incentives for rare disease research.

Question 50: Which of the following drugs requires therapeutic drug monitoring?

A. Metformin
B. Propranolol
C. Warfarin
D. Phenytoin (Correct Answer)

Explanation: ### Explanation **Correct Option: D (Phenytoin)** Phenytoin is a classic candidate for **Therapeutic Drug Monitoring (TDM)** due to its unique pharmacokinetic profile. It follows **zero-order (non-linear) kinetics** at therapeutic concentrations. This means that as the metabolic enzymes (CYP2C9) become saturated, even a small increase in dose can lead to a disproportionately large increase in plasma concentration, resulting in toxicity. Additionally, Phenytoin has a **narrow therapeutic index** (10–20 µg/mL), where the margin between the effective dose and the toxic dose is very slim. **Analysis of Incorrect Options:** * **A. Metformin:** Its efficacy is monitored by clinical parameters like blood glucose levels and HbA1c. It has a wide safety margin and predictable kinetics. * **B. Propranolol:** The clinical response (reduction in heart rate or blood pressure) is easily measurable at the bedside, making plasma level monitoring unnecessary. * **C. Warfarin:** While Warfarin has a narrow therapeutic index, it is monitored using **PT/INR** (a pharmacodynamic marker) rather than measuring the drug concentration in the blood. **High-Yield Clinical Pearls for NEET-PG:** * **Criteria for TDM:** Narrow therapeutic index, high inter-individual variability, non-linear kinetics, and lack of easily measurable clinical markers. * **Mnemonic for TDM Drugs:** "**L**earn **T**he **V**ery **P**oisonous **D**rugs **C**arefully" (**L**ithium, **T**heophylline/Tricyclic antidepressants, **V**alproate, **P**henytoin, **D**igoxin, **C**yclosporine). * **Phenytoin Toxicity:** Characterized by nystagmus (earliest sign), ataxia, and gum hypertrophy. * **Exception:** If a drug has a measurable physiological effect (e.g., BP for antihypertensives, INR for Warfarin), TDM is generally not required.

Question 51: A patient with history of ischemic stroke was started on clopidogrel. However, she had another attack of stroke after 6 months. Which of the following is likely to be responsible for the failure of clopidogrel in this patient?

A. Upregulation of CYP1A1
B. Downregulation of CYP2E1
C. Downregulation of CYP2C19 (Correct Answer)
D. Downregulation of CYP2D6

Explanation: ***Reduced function/Loss of function of CYP2C19*** - **Clopidogrel** is a **prodrug** that requires activation by **hepatic cytochrome P450 (CYP) enzymes**, primarily **CYP2C19**, to its active metabolite. - **Genetic polymorphisms** causing **reduced function or loss of function of CYP2C19** (e.g., CYP2C19*2, *3 alleles) result in insufficient conversion of clopidogrel to its active form, leading to **clopidogrel resistance** and increased risk of thrombotic events like recurrent stroke. - These **poor metabolizers** have significantly reduced antiplatelet response to standard clopidogrel doses. *Upregulation of CYP1A1* - **CYP1A1** is involved in the metabolism of various xenobiotics but plays a **minimal role** in clopidogrel activation. - Upregulation of CYP1A1 would not be a primary factor in clopidogrel failure as it is not the main enzyme responsible for its bioactivation. *Downregulation of CYP2E1* - **CYP2E1** is primarily involved in the metabolism of small organic molecules, some drugs, and toxins, and has **no significant role** in the bioactivation of clopidogrel. - Therefore, changes in its expression would not impact clopidogrel's efficacy. *Downregulation of CYP2D6* - **CYP2D6** is a major enzyme involved in the metabolism of many psychoactive drugs, beta-blockers, and opioids, but plays only a **minor role** in clopidogrel activation compared to CYP2C19. - Downregulation of CYP2D6 would not be the primary cause of clopidogrel failure.

Question 52: Prolonged apnea may occur in patients with a genetically determined abnormal variant of cholinesterase following intravenous administration of

A. Mivacurium
B. Tubocurarine
C. Succinylcholine
D. Succinylcholine or mivacurium (Correct Answer)

Explanation: ***Succinylcholine or mivacurium*** - **Both succinylcholine and mivacurium** are metabolized by **plasma cholinesterase (pseudocholinesterase)**. - Patients with **atypical (abnormal) plasma cholinesterase** have reduced or absent enzyme activity, leading to **prolonged duration of action** and extended paralysis/apnea with both drugs. - **Succinylcholine** is a depolarizing neuromuscular blocker whose duration increases from 5-10 minutes to several hours in affected patients. - **Mivacurium** is the only non-depolarizing neuromuscular blocker metabolized by plasma cholinesterase; its duration increases from 15-20 minutes to several hours in these patients. - This is a classic **pharmacogenetic** condition requiring prolonged ventilatory support until the drug effect dissipates. *Succinylcholine (alone)* - While succinylcholine is affected by atypical cholinesterase, this option is incomplete as it excludes mivacurium, which is equally affected by the genetic variant. *Mivacurium (alone)* - While mivacurium is affected by atypical cholinesterase, this option is incomplete as it excludes succinylcholine, the more commonly used drug that is also affected. *Tubocurarine* - **Tubocurarine** is a non-depolarizing neuromuscular blocker that undergoes **renal excretion** and hepatic metabolism, not plasma cholinesterase degradation. - Its duration of action is **not affected** by variations in cholinesterase activity.

Question 53: Which enzyme deficiency is associated with severe reactions to sulfonamides in HIV patients?

A. N-acetyltransferase
B. Glucose-6-phosphate dehydrogenase (Correct Answer)
C. Cytochrome P450 2D6
D. Glutathione S-transferase

Explanation: ***Glucose-6-phosphate dehydrogenase*** - **G6PD deficiency** is the key enzyme deficiency associated with severe hemolytic reactions to sulfonamides - G6PD is essential for protecting RBCs against **oxidative stress** by maintaining glutathione in its reduced form - Sulfonamides (especially cotrimoxazole used for PCP prophylaxis in HIV) cause **oxidative damage** leading to **acute hemolytic anemia** in G6PD-deficient patients - In **HIV patients**, this is particularly important as sulfonamides are commonly prescribed *N-acetyltransferase* - NAT enzyme is involved in Phase II metabolism of sulfonamides through acetylation - Deficiency leads to **slow acetylator phenotype** with higher drug levels - Associated with different toxicities like hypersensitivity reactions and lupus-like syndrome - Does not cause the acute hemolytic anemia characteristic of G6PD deficiency *Cytochrome P450 2D6* - CYP2D6 metabolizes codeine, tramadol, antidepressants, and antipsychotics - Plays **minimal role** in sulfonamide metabolism - Deficiency affects metabolism of its specific substrates, not sulfonamides *Glutathione S-transferase* - GST enzymes conjugate glutathione to xenobiotics for detoxification - While involved in oxidative stress protection, GST deficiency is not the primary cause of severe sulfonamide reactions - G6PD deficiency is the specific enzymatic defect causing acute hemolytic crisis with sulfonamides

Question 54: Best predictor of varenicline response in smoking cessation is:

A. Nicotine dependence score
B. CHRNA5 gene variant (Correct Answer)
C. Pack-years
D. Previous quit attempts

Explanation: ***CHRNA5 gene variant*** - Genetic variations in the **CHRNA5 gene** (part of the CHRNA5-CHRNA3-CHRNB4 gene cluster on chromosome 15q25) encode subunits of nicotinic acetylcholine receptors and influence nicotine dependence and smoking behavior. - In the context of **pharmacogenomics**, CHRNA5 variants represent the **biological/genetic predictor** of treatment response, distinguishing individual variability in varenicline efficacy. - Among the options provided, this is the only **genetic factor** that can predict differential drug response at a molecular level. *Nicotine dependence score* - While a higher **nicotine dependence score** (measured by tools like Fagerström Test) indicates greater addiction severity and may correlate with treatment outcomes, it is a **clinical assessment**, not a biological predictor. - It reflects the phenotype (observable addiction) rather than the underlying genetic mechanism affecting drug response. *Pack-years* - **Pack-years** quantify cumulative tobacco exposure (packs per day × years smoked), indicating health risk and damage burden. - This is a **historical exposure metric**, not a predictor of varenicline's pharmacological efficacy or individual response variability. *Previous quit attempts* - The number of **previous quit attempts** reflects **behavioral patterns** and motivation but does not predict how an individual's nicotinic receptors will respond to varenicline. - This is a psychosocial factor rather than a pharmacogenomic predictor of drug response.

Question 55: In patients undergoing INH therapy, which group is least likely to develop neuropathy?

A. Having malnutrition
B. Alcoholics
C. Fast acetylators (Correct Answer)
D. Vitamin B complex deficiency

Explanation: ***Fast acetylators*** - **Fast acetylators** metabolize INH more quickly, leading to lower systemic drug levels and thus a reduced risk of adverse effects like neuropathy. - Neuropathy associated with INH is primarily due to **pyridoxine (vitamin B6) depletion**, which is less pronounced if the drug is rapidly cleared. *Having malnutrition* - **Malnutrition** often involves deficiencies in essential vitamins, including vitamin B6, which is crucial for preventing INH-induced neuropathy. - Patients with poor nutritional status are at a **higher risk** of developing neuropathy during INH therapy due to pre-existing vitamin B6 depletion. *Alcoholics* - **Alcoholism** is strongly associated with deficiencies in various B vitamins, particularly **pyridoxine (vitamin B6)**, due to poor diet and impaired absorption. - This pre-existing deficiency makes alcoholics **highly susceptible** to INH-induced neuropathy. *Vitamin B complex deficiency* - A **deficiency in vitamin B complex**, especially pyridoxine (B6), is a known risk factor for INH-induced neuropathy. - Isoniazid interferes with **pyridoxine metabolism**, and those with pre-existing deficiency are more vulnerable to this adverse effect.

Question 56: Which drug is contraindicated in G6PD deficiency?

A. Primaquine (Correct Answer)
B. Chloroquine
C. Quinine
D. All of the options

Explanation: ***Primaquine*** - **Primaquine** is an antimalarial drug that generates **severe oxidative stress** in red blood cells. - It is **definitively contraindicated** in **G6PD deficiency** as it consistently causes **acute hemolytic anemia**. - Among antimalarials, primaquine poses the **highest risk** and should **never be used** in G6PD-deficient patients. - It is used for radical cure of P. vivax and P. ovale malaria, but alternative regimens must be used in G6PD deficiency. *Chloroquine* - **Chloroquine** can cause hemolysis in **G6PD deficiency**, though the risk is **lower than primaquine**. - It is **not considered fully safe** and should be used with **caution** in G6PD-deficient patients. - At standard doses, the risk is moderate, but hemolysis can occur, especially in certain G6PD variants. - However, it is not absolutely contraindicated and may be used when benefits outweigh risks with close monitoring. *Quinine* - **Quinine** can also cause **hemolysis** in patients with **G6PD deficiency**. - The risk varies with G6PD variant severity and dosage. - In **severe G6PD deficiency**, quinine should be avoided when alternatives are available. - While less consistently problematic than primaquine, it still requires caution and monitoring. *All of the options* - This option is incorrect in the context of this question because **primaquine** is the **most consistently and severely contraindicated** drug. - While chloroquine and quinine can cause hemolysis, they have **variable risk profiles** and may be used cautiously in some situations, unlike primaquine which is **absolutely contraindicated**. - The question asks for "which drug" (singular), indicating primaquine as the primary answer due to its consistent and severe risk.

Question 57: What does the Dibucaine number indicate in clinical practice?

A. Gives percentage of lignocaine levels in blood
B. Gives percentage of metabolised lignocaine levels
C. Gives percentage of succinylcholine in blood
D. Indicates the percentage inhibition of pseudocholinesterase activity by dibucaine (Correct Answer)

Explanation: **Indicates the percentage inhibition of pseudocholinesterase activity by dibucaine** - The **Dibucaine number** quantifies the extent to which the local anesthetic **dibucaine** inhibits the enzyme **pseudocholinesterase**. - A low Dibucaine number suggests an atypical variant of pseudocholinesterase, leading to prolonged breakdown of drugs like **succinylcholine**. *Gives percentage of lignocaine levels in blood* - The Dibucaine number is not used to measure **lignocaine (lidocaine) levels** in the blood. - Lignocaine levels are typically measured directly through **chromatographic assays** when therapeutic monitoring is needed. *Gives percentage of metabolised lignocaine levels* - The Dibucaine number has no direct correlation with the **metabolism of lignocaine**. - Lignocaine is primarily metabolized by **hepatic cytochrome P450 enzymes**, not pseudocholinesterase. *Gives percentage of succinylcholine in blood* - While related to succinylcholine metabolism, the Dibucaine number does **not measure succinylcholine levels** in the blood. - Instead, it assesses the functionality of the enzyme responsible for **succinylcholine degradation**.

Question 58: HLA-B5701 is an allele associated with hypersensitivity to abacavir. Which of the following is the parent allele of HLA-B5701?

A. HLA-B*5
B. HLA-B*51
C. HLA-DQ2
D. HLA-B*57 (Correct Answer)

Explanation: ***HLA-B\*57*** - **HLA-B*57** is the parent allele for **HLA-B*5701**, indicating it is the broader serotype under which specific alleles like *5701 are classified [1]. - The notation **HLA-B\*57** signifies a specific **HLA class I** allele group [1]. *HLA-B\*5* - This option is **incomplete** as an HLA allele notation; it lacks the specific group designation often indicated by two or three digits following the asterisk. - While "B5" exists as a serotype, **"HLA-B*5"** itself is not a standard, complete allele designation reflecting a specific gene variant. *HLA-B\*51* - **HLA-B\*51** is a specific **HLA class I** allele, but it is not directly related to or the parent group of **HLA-B\*5701**. - It is known to be associated with Behcet's disease, a different clinical condition not related to abacavir hypersensitivity. *HLA-DQ2* - **HLA-DQ2** is an allele of **HLA class II**, while **HLA-B\*5701** is an **HLA class I** allele. - Though both are HLA alleles, they belong to different classes and are associated with different disease contexts, with **HLA-DQ2 typically linked to celiac disease**.

Question 59: Hemolysis in G6PD deficiency is precipitated by all of the following except:

A. Cotrimoxazole
B. Quinine
C. Penicillin (Correct Answer)
D. Dapsone

Explanation: ***Penicillin*** - **Penicillin** is generally considered safe in individuals with G6PD deficiency and typically does not precipitate **hemolysis**. - Its mechanism of action does not involve the generation of **oxidative stress** that would overwhelm the deficient G6PD pathway. *Dapsone* - **Dapsone** is known to cause **oxidative stress** in red blood cells, making it a strong precipitating agent for hemolysis in G6PD deficient individuals. - It is an **antimicrobial** agent often used in conditions like leprosy. *Cotrimoxazole* - **Cotrimoxazole**, a combination of **trimethoprim** and **sulfamethoxazole**, is a potent oxidizing agent. - It can induce significant **hemolysis** in patients with G6PD deficiency due to its oxidative properties. *Quinine* - **Quinine**, an **antimalarial** drug, is another agent that can cause oxidative stress in red blood cells. - It is recognized as a drug that can precipitate **hemolytic crises** in G6PD deficient individuals.

Question 60: The risk of carbamazepine-induced Stevens-Johnson syndrome is increased in the presence of which of the following genes?

A. HLA-B* 5801
B. HLA-B* 1502 (Correct Answer)
C. HLA-B* 5701
D. HLA-B*27

Explanation: ***HLA-B\* 1502*** - The **HLA-B\*1502** allele is strongly associated with an increased risk of **carbamazepine-induced Stevens-Johnson syndrome (SJS)** and **toxic epidermal necrolysis (TEN)**, particularly in individuals of Asian ancestry. - Screening for this allele is often recommended before initiating **carbamazepine** in at-risk populations. *HLA-B\* 5801* - The **HLA-B\*5801** allele is associated with an increased risk of **allopurinol-induced severe cutaneous adverse reactions (SCARs)**, including SJS and TEN. - It is not directly linked to carbamazepine-induced SJS. *HLA-B\* 5701* - The **HLA-B\*5701** allele is strongly associated with a higher risk of **abacavir hypersensitivity reaction** [1]. - It is recommended to screen for this allele before starting abacavir therapy. *HLA-B 27* - **HLA-B27** is primarily associated with **seronegative spondyloarthropathies**, such as **ankylosing spondylitis** and **reactive arthritis**. - It does not have a known association with carbamazepine-induced SJS.

Question 61: Which of the following is not considered a pharmacogenetic condition?

A. Adenosine deaminase deficiency (Correct Answer)
B. Coumarin insensitivity
C. G6PD deficiency
D. Malignant hyperthermia

Explanation: ***Adenosine deaminase deficiency*** - **Adenosine deaminase deficiency** (ADA deficiency) is an **autosomal recessive** metabolic disorder causing severe immunodeficiency, primarily affecting gene function rather than drug response. - While it can be treated with enzyme replacement therapies or gene therapy, it is not primarily characterized by an altered response to standard therapeutic drugs. *Coumarin insensitivity* - **Coumarin insensitivity** refers to an individual's reduced response to **warfarin (a coumarin derivative)**, requiring higher doses to achieve effective anticoagulation. - This is a well-documented **pharmacogenetic condition**, often linked to variations in genes like *CYP2C9* and *VKORC1*. *G6PD deficiency* - **Glucose-6-phosphate dehydrogenase (G6PD) deficiency** is an X-linked genetic disorder that can lead to **hemolytic anemia** upon exposure to certain drugs (e.g., antimalarials, sulfonamides, aspirin) and fava beans [1]. - It is a classic example of a **pharmacogenetic condition** where genetic variations dictate drug-induced adverse reactions [1]. *Malignant hyperthermia* - **Malignant hyperthermia** is a life-threatening, inherited disorder triggered by certain **inhalation anesthetics** (e.g., halothane, isoflurane) and the **depolarizing muscle relaxant succinylcholine**. - This condition is caused by mutations in genes involved in calcium regulation in muscle cells (e.g., *RYR1*) and is a critical **pharmacogenetic response**.

Practice by Chapter

Genetic Basis of Drug Response

Practice Questions

Pharmacogenomic Testing

Practice Questions

Cytochrome P450 Polymorphisms

Practice Questions

Pharmacogenomics of Drug Transporters

Practice Questions

Pharmacogenomics in Oncology

Practice Questions

Pharmacogenomics in Cardiovascular Therapeutics

Practice Questions

Pharmacogenomics in Psychiatry

Practice Questions

Personalized Medicine Approaches

Practice Questions

Ethical Considerations in Pharmacogenomics

Practice Questions

Implementation of Pharmacogenomics in Clinical Practice

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free